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I 
Summary 
Streptococcus pyogenes infects more than 600 million humans every year. In addition to a variety of acute 
infections, this bacterium causes acute rheumatic fever (ARF), an autoimmune sequela that frequently 
develops into rheumatic heart disease (RHD). RHD is a leading health problem in several low-resource 
regions in the world, thus remains a major public health concern. Evidence is crystallizing that 
Streptococcus dysgalactiae subsp. equisimilis is also a cause for ARF and RHD. 
A vast variety of S. pyogenes serotypes and corresponding genotypes are distinguished based on variations 
in M protein or the M protein coding emm gene, respectively. M proteins are potent virulence factors and a 
major target of the human antibody response against this bacterium. In response to the immunity, the 
portion of the emm gene that encodes the N-terminal sequence of the M protein is under strong diversifying 
selection pressure and currently more than 200 distinct emm-types have been identified. Moreover, the M 
protein has been implicated in the pathogenesis of ARF. This protein triggers autoimmunity by molecular 
mimicry of host proteins with coiled-coil structure such as myosin or laminin. In addition, a collagen-
binding A/T/E)xYLxx(L/F)N motif occurs in the N-terminal type specific part of M proteins that evoke 
collagen IV autoimmunity. This immune response against collagen IV is observed in ARF patients, but is 
not a cross reaction between M protein and the host protein as in molecular mimicry. As these observations 
suggested a link between the collagen binding motif and the autoimmune responses in ARF, the motif is 
referred to as “peptide associated with rheumatic fever” (PARF). However, the role of collagen-binding 
and of other properties of M proteins in triggering autoimmunity against collagen IV and consequences of 
this host response remain elusive. 
Therefore, full-length M proteins of different emm-types were tested in this work for their ability to bind 
collagens I or IV and to evoke autoimmune responses against these collagens and the coiled-coil proteins 
myosin and laminin in a mouse model. The work proved for the first time that induction of collagen IV 
autoimmunity is PARF-specific, thus not caused by other parts or properties of the M protein. Furthermore, 
sufficient affinity of PARF carrying M proteins for collagen IV appeared to be crucial for triggering the 
aforementioned autoimmunity. 
Further evidence for the role of PARF as a trigger of autoimmunity came from experiments with 
recombinant protein that contained all known naturally occuring PARF motifs (PARF tandem). Other than 
a synthetic PARF peptide (peptide 17) that was optimized for collagen binding, the multivalent PARF 
tandem induced autoimmunity against collagen IV and myosin in mice.  
Due to the potential of PARF-positive M proteins to trigger autoimmunity, the corresponding strains may 
be important targets for vaccines. Notably, PARF tandem induced the production of opsonizing antibodies 
in rabbit, that reacted with PARF-positive M proteins of two distinct types. As immunization with PARF 
tandem caused autoimmunity too, a vaccine strategy that targets PARF would require further development. 
Collagen-binding PARF occurs in about 7% of the S. pyogenes isolates that infect human beings 
worldwide. Moreover, the discovery of Spa as a novel collagen binding protein that triggers autoimmunity 
against collagen, despite lacking a PARF motif, broadens the spectrum of potential rheumatogenic factors 
in S. pyogenes. For the first time, a trigger of autoimmunity was identified in an emm-type (emm18) that is 
clearly associated with several outbreaks of ARF in the USA.  
 
The presented work clearly points towards a role of interactions between host and microbial proteins in 
triggering autoimmunity and may have uncovered a new facet in the pathogenesis of autoimmune diseases 
in general. However, more research is needed for a comprehensive understanding of the underlying 
processes and their medical significance. Currently, we may only see the tip of an iceberg.  
II 
Zusammenfassung 
Streptococcus pyogenes infiziert mehr als 600 Millionen Menschen im Jahr. Außer einer Vielfalt von 
akuten Infektionen, verursacht das Bakterium akutes rheumatisches Fieber (ARF), eine 
Autoimmunerkrankung, die häufig zur rheumatischen Herzerkrankung führt (RHD). RHD ist ein führendes 
Gesundheitsproblem in einigen Schwellen- und Entwicklungsländern. Es mehren sich die Hinweise, dass 
auch Streptococcus dysgalactiae subsp. equisimilis eine Ursache für ARF und RHD ist. 
Eine enorme Vielfalt an S. pyogenes Serotypen und zugehörigen Genotypen werden auf Grund von 
Variationen im M Protein bzw. dem M-Protein-kodierenden emm-Gen unterschieden. Das M Protein ist ein 
sehr wirksamer Virulenzfaktor und Hauptangriffspunkt für die spezifische Immunantwort des Menschen. 
Letztere übt einen starken diversifizierenden Selektionsdruck auf den Teil des emm-Gens aus, der für den 
N-terminus kodiert, weshalb mehr as 200 verschiedene emm-Typen bekannt sind. Darüber hinaus wurde 
das M protein mit der Pathogenese von ARF im Zusammenhang gebracht. Das Protein löst Autoimmunität 
durch molekulare Mimikry von Wirtsproteinen mit Coiled-coil-Struktur aus wie Myosin und Laminin. 
Außerdem kommt in einigen N-terminalen typspezifischen Enden von M proteinen, die eine 
Autoimmunität gegen Kollagen IV auslösen, das kollagenbindende A/T/E)xYLxx(L/F)N-Motiv vor. Diese 
Immunantwort gegen Kollagen IV wird auch in Patienten mit ARF beobachtet. Sie ist aber keine 
Kreuzreaktion zwischen dem Wirtsprotein und dem M protein wie im Falle der molekularen Mimikry. 
Weil diese Beobachtungen einen Zusammenhang zwischen dem Kollagenbindungsmotiv und 
Autoimmunantworten in ARF nahelegen, wird das Motiv “peptide associated with rheumatic fever” 
(PARF) genannt. Die Rolle der Kollagenbindung und von anderen Eigenschaften des M Proteins im 
Auslösen der Autoimmunität gegen Kollagen IV und die Folgen dieser Wirtsantwort sind bisher nicht 
ausreichend untersucht. 
Deshalb wurden in dieser Arbeit M proteine von verschiedenen emm-Typen auf ihre Fähigkeit getestet 
Kollagen I oder IV zu binden und Autoimmunantworten gegen diese Kollagene und die Coiled-coil 
Proteine Myosin oder Laminin auszulösen. Diese Arbeit wies zum ersten Mal nach, dass die Induktion der 
Kollagen-IV-Autoimmunität PARF-spezifisch ist und folglich nicht durch andere Teile oder Eigenschaften 
des M Proteins verursacht wird. Darüber hinaus schien eine ausreichende Affinität von PARF-positiven M 
Proteinen für Kollagen IV unabdingbar für das Auslösen der oben genannten Autoimmunität zu sein. 
Weitere Beweise für die Rolle von PARF als Auslöser für Autoimmunität kamen von Experimenten mit 
einem rekombinanten Protein, das alle bisher bekannten natürlich vorkommenden PARF-Motive enthielt 
(PARF tandem). Anders als ein synthetisches PARF-Peptid (Peptid 17), das auf Kollagenbindung hin 
optimiert wurde, induzierte PARF tandem Autoimmunität gegen Kollagen und Myosin in Mäusen. 
Wegen des Potentials PARF-positiver M Proteine Autoimmunität auszulösen, könnten die zugehörigen 
Stämme wichtige Ziele für Impfstoffe sein. Bemerkenswert war, dass PARF tandem die Produktion 
opsonisierender Antikörper im Kanninchen induzierte, die gegen zwei unterschiedliche M proteine 
reagierten. Da die Immunisierung mit PARF tandem aber auch Autoimmunität verursachte, müsste eine 
Impfstrategie, die auf PARF zielt, weiterentwickelt werden. 
Kollagenbindendes PARF kommt in etwa 7% der S. pyogenes-Isolate vor, die den Menschen infizieren. 
Die Entdeckung von Spa als neues kollagenbindendes Protein, das Autoimmunität gegen Kollagen auslöst, 
obwohl es kein PARF-Motiv trägt, erweitert das Spektrum potentieller rheumatogener Faktoren in S. 
pyogenes. Zum ersten Mal wurde ein Auslöser von Autoimmunität in einem emm-Typ (emm18) entdeckt, 
der nachweislich mit mehreren Ausbrüchen von ARF und RHD in den USA assoziiert ist. 
Die vorliegende Arbeit weist klar auf eine Rolle von Interaktionen zwischen Wirts- und Mikrobiellen 
Proteinen in der Entstehung von Autoimmunität hin und könnte generell eine neue Facette in der 
Pathogenese von Autoimmunerkrankungen aufgedeckt haben. Es ist jedoch mehr Forschung erforderlich, 
um die zugrundeliegenden Prozesse und ihre medizinische Signifikanz umfassend zu verstehen. Wir sehen 
gegenwärtig vielleicht nur die Spitze eines Eisbergs. 
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A 
ARF: acute rheumatic fever 
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1.1 The genus Streptococcus 
The genus Streptococcus comprises species of non-motile Gram-positive extracellular 
bacteria. Streptococci are lactic acid fermenting bacteria and many of them colonize or infect 
humans or animals. The name Streptococcus, from the Greek (streptos = twisted chain) and 
(coccus = spherical), refers to the characteristic way in which these spherical bacteria grow in 
chains, like pearls on a string (Fig. 1). 
 
Figure 1: Chains of S. pyogenes at 5000 fold magnification. The picture was kindly provided by Prof. M. 
Rohde (HZI-Braunschweig). 
The concept of species is not well defined in bacteriology and faces its limits when studying 
bacterial genomes, because of lateral gene transfer. During bacterial evolution, lateral gene 
transfer is responsible of the movement of genetic material even between distantly related 
bacteria, blurring the borders between taxonomic entities (1). However, grouping of bacteria 
based on metabolic properties or their genome correlates with their ecology and, not least, 
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their pathogenic potential. Hence, dividing bacteria into species is of great value in research, 
biotechnology and medicine. 
The genus Streptococcus includes more than 50 genetically distinct species and subspecies 
(2-3), which are divided into six groups: the mitis group, the anginosus group, the salivarius 
group, the mutans group, the bovis group and the pyogenic group (Fig. 2). Streptococcal 
species differ substantially in their ecology and their pathogenic potential in humans or 
animals. The pyogenic group for instance contains prominent human pathogenic streptococci 
such as Streptococcus pyogenes, Streptococcus agalactiae and Streptococcus dysgalactiae 
subsp. equisimilis (1.3). 
 
Figure 2: Neighbor joining tree of a multilocus sequence analysis
 
of 852 streptococcal isolates of different 
(sub-) species. Streptococcal groups and selected (sub-) species are indicated in light grey and dark grey, 
respectively. The analysis comprises data of different studies (4-5-6) 
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1.2 Distinguishing streptococci 
1.2.1 Hemolysis 
A historically early method to distinguish streptococci is based on their ability to lyse 
erythrocytes on blood agar plates and to degrade the hemoglobin, a phenomenon called 
hemolysis. According to the degree of hemolysis, these bacteria are divided in α, β and γ-
hemolytic streptococci (7). α-hemolytic streptococci oxidize the iron ion of the hem and 
partially degrade this prosthetic group of the hemoglobin, causing incomplete hemolysis. This 
appears as a greenish halo that surrounds the bacterial colonies on blood agar. β-hemolytic 
species cause complete rupture of the erythrocytes and degrade the hem completely. On blood 
agar plates this appears as a clear zone that surrounds the bacterial colonies. γ-hemolytic 
streptococci do not cause hemolysis. The type of hemolysis is a valuable diagnostic 
parameter, as important pathogenic streptococci are β-hemolytic (8). 
1.2.2 Lancefield-grouping  
Streptococci are further distinguished by a serological method that has been established by 
Rebecca Lancefield in 1932 (9). This method is based on group-specific antigens on the 
bacterial surface called Lancefield group antigens. Lancefield-grouping separates streptococci 
into more than 20 distinct serological groups, which were designated with Latin letters 
starting from A. This method is widely used in diagnosis, as it identifies two prominent 
human pathogenic streptococcal species, S. pyogenes (group A) and S. agalactiae (group B). 
However, this method fails to distinguish between different taxonomic entities of other 
Lancefield groups, for instance streptococci of the Lancefield groups C and G (GCGS) (1.4 
SDSE). GCGS comprise several species with different pathogenic potential in humans or 
animals (10). Consequently, Lancefield-grouping is of certain but limited value in the 
characterization of streptococci and diagnosis of streptococcal infections.  
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1.2.3 DNA based methods 
As mentioned above, the concept of species is not well defined in bacteriology and 
consequently, there is no clear-cut definition for bacterial species. More or less arbitrary 
thresholds of DNA homology are used when distinguishing streptococcal species (11). The 
percentage of DNA sequence homology is determined by DNA-DNA hybridization or whole 
genome sequencing (11-12). Other than DNA-DNA hybridization, whole genome 
sequencing delivers additional information about the gene content or genetic rearrangements 
in the investigated bacteria. Selected members of the genus are described below. 
1.3 Viridans streptococci and the bovis group 
The name viridans streptococci, derives from “viridis”, the Latin word for green. It is a non-
taxonomic term for streptococci that produce a greenish coloration on blood agar plates, due 
to α-hemolysis (1.2 Hemolysis). While the majority of the viridans streptococci is α-
hemolytic, some strains of these bacteria are β- or γ-hemolytic and show other phenotypic 
inconsistencies even within species (9). Most of the viridans streptococci are commensals of 
the human oral cavity, which are referred to as oral streptococci. Although they are 
commensals in certain niches of the human host, viridans streptococci are facultative 
pathogens (6). They comprise four out of the six groups of streptococci: the anginosus group, 
the mitis group, the salivarius group and the mutans group (6). 
The anginosus group includes streptococci that can be part of the normal flora of the oral 
cavity, the urogenital tract and the gastrointestinal tract of humans. Nonetheless, streptococci 
from the anginosus group are facultative human pathogens (5). Infections with these 
streptococci can have a pyogenic (pus-forming) character and some strains share typical 
properties with pyogenic streptococci like β-hemolysis and Lancefield antigens A, C or G. 
Other strains are not groupable or belong to group F (13). The spectrum of diseases that is 
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caused by the anginosus group comprises severe infections in the oral cavity, the skin, the 
central nervous system and in inner organs like the brain or the liver. (5) Streptococci of this 
group have a characteristic and pronounced tendency to cause abscesses and their infections 
can become life-threatening (14). 
The mutans group is named after the prototypic bacteria of this group, S. mutans, which is a 
part of the dental plaque and the leading cause for dental caries in humans (15). 
Streptococci of the mitis and of the salivarius group colonize the human oral cavity where 
they are involved in caries formation and gingivitis (16). Moreover, they can invade the blood 
stream, occasionally causing life-threatening diseases (17). Streptococci of the salivarius 
group are a frequent cause of septicemia in neutropenic patients (18) while streptococci of the 
mitis group are the leading causes of streptococcal endocarditis (6-19). This is an infection of 
the endocardium that usually involves the heart valves and has high morbidity and mortality 
world-wide (6). An important predisposing factor for infective endocarditis is acute rheumatic 
fever (20) (1.7.2 ARF and RHD). 
The bovis group includes streptococci that are inhabitants of the human gastrointestinal tract 
(20-21). These streptococci cause bacteraemia and endocarditis, often associated with 
perforating gastrointestinal diseases (22) or colorectal cancer (23-24). A potential role of 
these bacteria in the development of cancer is under investigation. It is not yet clear whether 
bovis group streptococci are causative for gastrointestinal malignancy or whether malignancy 
facilitates colonization with these bacteria.  
1.4 Pyogenic streptococci 
The pyogenic group includes the most important β-hemolytic streptococcal pathogens that 
cause various suppurative (pus-producing) infections in humans or animals. Production of pus 
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is the result of the attraction and activation of leucocytes, at the site of infection. As a defence 
against these cells of the immune system, streptococci produce toxins that kill the leucocytes, 
contributing to the pyogenic character of the infection. A well-known human pathogen of the 
pyogenic group is S. agalactiae, which forms the Lancefield group B (1.2 Lancefield-
grouping). This bacterium is part of the normal flora of the gastrointestinal and genital tract of 
humans and animals. As a colonizer of the female genital tract, it poses a significant obstetric 
problem. S. agalactiae causes puerperal fever and is the leading cause of bacterial septicemia 
and meningitis in newborns children (25). Other important human pathogens of the pyogenic 
group are S. pyogenes and S. dysgalactiae subsp. equisimilis (SDSE). Worldwide, they are 
responsible for more than 800 million infections every year (26). 
1.4.1 Streptococcus pyogenes  
S. pyogenes is a β-hemolytic Streptococcus of the pyogenic group and belongs to the 
Lancefield group A. This human specific pathogen is occasionally found in the flora of the 
upper respiratory tract of symptom free individuals (27). To date, humans are the only known 
reservoir of these bacteria, which are responsible for a wide spectrum of acute infections and 
cause severe post-infection sequelae (28). Worldwide S. pyogenes is the leading cause of 
bacterial pharyngitis (strep throat) and causes localized skin infections (pyoderma). If deeper 
tissues become infected with this pathogen, the production of bacterial toxins in combination 
with overreacting immune cells can lead to severe soft tissue infections such as necrotizing 
fasciitis. Necrotizing fasciitis is a life-threatening condition, often requiring surgical 
debridement of infected tissue or amputation. Even intensively treated necrotizing fasciitis 
can lead to death by streptococcal toxic shock syndrome (STSS) (29). Streptococcal toxins 
are also the cause of the characteristic rush that appears in scarlet fever, a disease that 
commonly affects children (30). Furthermore, acute streptococcal infections can trigger 
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deleterious immune responses that lead to the post-streptococcal sequelae acute rheumatic 
fever (ARF) and post-streptococcal glomerulonephritis (1.7.1). 
History is replete with descriptions of epidemics caused by S. pyogenes, highlighting the 
extraordinary virulence of this bacterium. Well-documented examples are the outbreaks of 
scarlet fever that occurred in the latter part of the 1880s in New York, Chicago and Norway 
and in which 25% to 30% of the infected children died (31-32). Improvement of socio-
economic conditions and the use of antibiotics during the last seven decades substantially 
reduced the incidence of infections caused by this pathogen in developed economic countries. 
Luckily, S. pyogenes has not yet developed resistance to β-lactam antibiotics, which remain 
the drugs of choice for treatment of acute streptococcal infections and for prevention of their 
sequelae (33). However, resistance of S. pyogenes to other antibiotics is on the rise. For 
instance, rates of resistance against erythromycin are high in several regions of the world (34-
35). Despite the availability of effective antibiotics, the incidence of streptococcal acute 
infections and prevalence of their sequelae remains high, accounting for more than half a 
million deaths per year (26). Failure of antibiotic treatment in individual cases and in further 
reducing the burden of S. pyogenes infections and sequelae creates a need for novel 
therapeutic approaches, including a vaccine against this bacterium. 
1.4.2 Streptococcus dysgalactiae subsp. equisimilis  
Streptococci of Lancefield group C and G (GCGS) are widely distributed in both animals and 
humans. They can be isolated from the normal flora of the pharynx, the skin, the 
gastrointestinal tract and the female genital tract, where they can also cause infections (36). 
GCGS can be divided into the species S. dysgalactiae, S. equi, S. canis and S. phocae. 
Moreover, some strains of anginosus group streptococci can carry the group C or G antigen 
(36). 
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For a long time, GCGS were considered mainly as animal pathogens. Moreover, taxonomic 
heterogeneity of GCGS led to difficulties in the diagnosis of infections caused by these 
pathogens. Therefore, the pathogenic potential that GCGS have in humans has long been 
underestimated. Today, due to improvements in diagnostic methods and increasing awareness, 
GCGS are recognized as relevant human pathogens (37-38). 
One pathogen of the GCGS is Streptococcus equi subsp. zooepidemicus. This zoonotic 
pathogen causes septicemia, purulent arthritis and post-streptococcal glomerulonephritis 
(PSGN) in humans (39). 
The dominant human pathogen of the GCGS is Streptococcus dysgalactiae subsp. equisimilis 
(SDSE) (40). Streptococci of this subspecies share many virulence factors with S. pyogenes 
(40), for instance the M protein (1.6.1), the C5a peptidase (41-42), the hyaluronic acid 
capsule (43), hemolysins (44) and the streptokinase (45). This is considered as the reason 
why SDSE infect humans in a way that closely resembles S. pyogenes infections. SDSE 
causes pharyngitis and suppurative skin and soft tissue infections (46-47). 
Experimental studies indicate a potential role of SDSE in triggering ARF (48-49). This is 
supported by epidemiological studies in some high prevalence regions for ARF, in which 
SDSE was the prevailing species in streptococcal pharyngitis. For instance, more than 60% of 
the throat isolates from a population of Indigenous Australians belonged to the subspecies 
SDSE, exceeding the isolation rate of S. pyogenes (50). Moreover, SDSE caused 75% of the 
streptococcal pharyngitis cases that occurred in 1978 in Lagos, Nigeria (51). 
The clinical importance of SDSE appears to be increasing (52). Recent epidemiological 
studies indicate an increase of invasive SDSE infections that often occur among elder or 
immunocompromised persons. Thus, it seems advisable to include these streptococci in health 
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care strategies that aim at reducing the burden of acute infections by pyogenic streptococci 
and their sequelae. 
1.5 Typing of S. pyogenes and SDSE isolates 
In order to investigate and describe the high variety of streptococcal isolates and to uncover 
correlations between certain types and certain ecological or pathogenic characteristics, 
researchers studied different serological and genetic markers of S. pyogenes. 
1.5.1 M serotyping 
S. pyogenes can be serologically divided into different M serotypes based on the streptococcal 
M antigen. The M antigen is a protein called M protein (1.6.1) and encoded by the emm gene. 
This surface bound protein differs between different isolates in its N-terminal sequence and 
elicits the production of specific antibodies in infected humans (53). Raised in animals, 
antibodies against M protein are exploited for discrimination of streptococcal isolates of more 
than 80 different serotypes (28). However, the vast variety of M proteins, difficulties in 
standardizing M serotyping, limited availability of standardized M antisera worldwide and 
ambiguities due to cross-reactivity in the identification of M types limit the value of this 
method for larger studies and epidemiological surveys. Therefore, M serotyping has been 
virtually replaced by the genetic emm-typing, a standardized method that is based on the 
sequence of the emm gene. It offers a higher resolution than M serotyping and is explained 
below. 
1.5.2 T-typing  
The T-typing assay, performed as an agglutination test, has been used in epidemiological 
investigations of S. pyogenes infections. The T antigen, coded by the tee gene, is an antigen 
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that was detected on the surface of more than 95% of S. pyogenes isolates (54). This method 
allowed typing S. pyogenes isolates of an outbreak, when the M serotype was not identifiable 
(55). Moreover, certain T serotypes are associated with specific M protein serotypes (55-56). 
This knowledge was used to preselect and reduce the M antisera required for M-typing, 
allowing a faster determination of the M type (27).  
1.5.3 Emm-typing 
The emm-typing, established by the Centers for Disease Control and Prevention (CDC), is a 
sequence based approach. For emm-typing, the 5’-sequence of the emm gene that encodes the 
hypervariable N-terminus of the M protein (1.6.1) is analysed and used to discriminate emm-
types and emm subtypes based on homology (57). Accordingly, the emm-type correlates with 
the M-type. This allows a fast and standardized typing of streptococci that is widely used for 
epidemiological studies on S. pyogenes, but also on SDSE, which also harbour an emm gene 
(58-59, 1.5.2). The emm gene is a genotype marker of S. pyogenes and SDSE and enables to 
type these bacterial isolates more efficiently than serological methods. An on-line database of 
emm genes is available, facilitating the exchange of information between different 
laboratories. The emm-typing revealed the diversity of S. pyogenes isolates (60). Currently, 
more than 200 emm-types have been identified and more will be identified in the future. 
Regional emm-typing data describe the spectrum of the circulating genotypes in defined 
geographic locations, which is of great scientific interest and of great importance in the design 
of streptococcal vaccines (1.5). 
1.5.4 Vir-typing 
Vir-typing is based on the multiple genes regulator (mga) region of S. pyogenes (1.6.1 and 
Fig. 3). The mga region is a 4 to 7 kb sequence that consists of the transcriptional regulator 
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Mga, genes that code for M and M-like proteins emm, enn, mrp/fcR and the scpA gene that 
encodes for the C5a peptidase (61). After amplification of the mga region by PCR, HaeIII and 
HinfI endonucleases are used to digest the amplicons in order to generate a restriction 
fragment length polymorphism (RFLP) profile. The resulting pattern determines the Vir-type, 
which correlates with the M type (62). 
1.5.5 MLST 
Multilocus sequence typing (MLST) is a general and widely used procedure for genotypic 
characterization of bacterial isolates. MLST of S. pyogenes isolates uses internal sequences of 
~ 500 base pairs of the seven housekeeping genes gki, gtr, murI, mutS, recP, xpt, and yqiL 
(62-63). According to allelic profiles, streptococcal isolates are assigned to a sequence type 
(ST). The advantage of MLST is that sequence data are unambiguous and the allelic profiles 
of isolates can easily be compared to those in a large central database via the Internet 
www.mlst.net (64). The high resolution of MLST is used to investigate evolutionary 
relationships among the bacteria and to track the development and spread of certain clonal 
complexes. Moreover, samples like clinical material can be analysed by PCR amplification in 
a culture independent manner. For these reasons, MLST is increasingly applied in research 
and clinical laboratories. 
1.5.6 Genotype diversity of S. pyogenes  
S. pyogenes isolates exhibit a high genetic diversity. The necessity to distinguish them for 
scientific and clinical purposes has driven the research towards several typing methods. In the 
past, serological methods were utilized to study the epidemiology of S. pyogenes isolates, in 
particular how their types correlate with certain manifestations of infections in humans. With 
the advent of DNA sequencing, serological methods have been replaced by genotyping, such 
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as the emm-typing. In addition, whole genome sequencing has shed light on the marked 
genetic differences that occur even between S. pyogenes bacteria of the same emm-type (65). 
In contrast to whole genome sequencing, the available typing methods are relatively 
inexpensive ways to investigate the genetic variety collections of streptococci and to study 
their distribution in defined geographic regions and/or over time. Among the several typing 
methods, emm-typing is the most widely used and shed light on large geographic differencies 
and a considerable dynamic of S pyogenes genotype distribution. 
Geographic regions differ in the diversity of emm-types and in prevalence of certain emm-
types. According to Smeesters et al., three groups are observed. In regions of the first and the 
second group, low emm-type  diversity with a few predominant emm-types is observed. North 
America and Western Europe belong to the first group, sharing a similar spectrum of emm-
types and the same prevalent types. The second group includes China and countries from 
Eastern Europe in which the predominant emm-types are different from the ones of the first 
group. In contrast, high emm-type diversity is observed in regions of the third group. In 
addition, no predominant emm-types were observed in these regions, most of which are high 
prevalence regions for ARF and RHD. For instance, newly industrialized countries like Brazil 
and India belong to the third group (66). 
Early studies tried to identify correlations between certain M or emm-types, and colonization 
sites or manifestation of disease like pharyngitis, skin infections or ARF (67). For instance, 
studies on endemic outbreaks of ARF in the USA indicated that the rheumatogenic potential 
of S. pyogenes is limited to few M types corresponding to emm M1, M3, M5, M6, M18, M19, 
and M24 (68-69-70). Further studies associated M3 serotype with ARF-like side effects and 
M18 was associated with ARF outbreaks in USA (71-72). Notably, these correlations could 
not be observed in other parts of the world where other M-types are prevalent and SDSE 
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infections are more frequent (73-74-75). Consequently, connections between emm-type and 
diseases remain somewhat uncertain. 
Although, epidemiological data were not able to picture the association between certain M 
types and certain human diseases, the genetic diversity of M protein is believed to play an 
important role in the spectrum of pathologies caused by S. pyogenes due to its several 
functions i.e. adhesion to the host, prevention of opsonophagocytosis, molecular mimicry with 
several host proteins and due to its possible role in triggering ARF (76). 
M and emm-typing shed light on serotype replacement of S. pyogenes. Serotype replacement 
has been observed over a period of 7 years in London, where the isolates of M-types 6, 49 and 
81 were replaced by types 1, 3 and 28 (77). Moreover, serotype replacement occurred within 
a short time period in a semi-closed community in the USA. In this community, during a time 
frame of three months, serotype M6 has replaced serotype M1, most likely due to post-
infectious protective responses against type M1 (78). 
Studying the emm-type distribution S. pyogenes and SDSE on the global scale as well as their 
prevalence in defined regions has provided valuable information for vaccine development. A 
vaccine designed to protect against emm-types that are prevalent in defined geographic 
regions could reduce the impact of streptococcal disease on human health (1.8.2). However, 
serotype replacement may be a problem for the success of such a vaccine. Thus, emm-typing 
could be an important and necessary method also in the future to studying serotype 
replacement that is driven by immune pressure due to vaccination. 
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1.6 M and M-like proteins of pyogenic streptococci  
1.6.1 M protein 
The M protein is a surface protein and one of the most studied virulence factors of S. 
pyogenes (79-80) and SDSE (81-82). Due to hypervariability in the 5’-end of the M protein 
gene (emm) more than 200 distinct emm-types have evolved and have been identified to date 
(www2a.cdc.gov/ncidod/biotech/strepblast.asp, as in November 2014). 
M proteins and the related M-like proteins (1.6.2) are encoded by the emm, mrp and enn 
genes. Those genes are tandemly arranged in the Mga region of the S. pyogenes genome and 
under positive control of the Mga (multi-gene activator) regulator (Fig. 3), which also 
regulates the expression of the genes sof and sfbX that are located in trans (Fig. 3, 83). The 
scpa gene that also included in the Mga region encodes the surface bound C5a peptidase, a 
virulence factor that is not related to the M proteins (83). The patterns of the Mga region can 
vary in S. pyogenes isolates according to their preferential colonization sites in the host. Mga 
pattern A, B and C caused mainly infectections of the oral tissues, whereas strains with 
pattern D were mostly isolated from the skin. S. pyogenes with a Mga region of pattern E 
were isolated at both oral and skin sites (84-85). 
 
Figure 3: Variants of the Mga region and their relationship to preferential colonization sites in the host. 
The figure was taken from Courtney et al. (86). 
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1.6.1.1 Structure of the M protein 
Electron microscopy revealed that the M proteins are arranged in a fur-like structure on the 
bacterial surface (Fig. 4). The M protein is a thread-like homodimer that forms a coiled-coil 
structure and extends ~50 nm from the streptococcal surface (87-88, Fig. 4). 
 
Figure 4: Electron micrograph of an ultra-thin section of a chain of S. pyogenes group A streptococci 
(20.000 fold magnification) The fur-like structure determined by the M proteins is clearly visible on the 
bacterial surface. (http://www.rockefeller.edu/vaf/chain20.php). 
Each chain of the M protein dimer consists of up to four distinct repeat regions, named A, B, 
C and D starting from the N-terminus (89). Although the overall organisation of the M 
protein is conserved, major differences exist, not only in the variable N-terminus, but also in 
the number of the repeats (76-90-91, Fig. 5). 
 
Figure 5: Schematic representation of the mature form of eight distinct M proteins. Presence, number and 
size of the repeats of the protein M6, M5, M1, M24, M53and M49 were deduced from (75). The composition of 
M3 and FOG were deduced from (92-93). 
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The common makeup of M protein monomers includes a conserved N-terminal signal peptide 
for extracellular secretion (94). The signal peptide sequence not only marks the molecule for 
export, but also targets secretion of the protein to the division septum (95). During maturation 
of the protein, the signal peptide is cleaved off by a signal peptidase and the M protein is 
covalently attached to the rigid peptidoglycan layer of the Gram-positive bacterial wall (Fig. 
6) through the action of an enzyme that is called sortase (96). After cleavage of the signal 
peptide, the mature M protein has a hypervariable N-terminus. More central parts are less 
variable and the C-terminus is conserved (76-79). 
 
Figure 6: Schematic structure of the M3 protein. Blocks A, B, C, and D designate the location of the sequence 
repeat blocks. Pro/Gly denotes the proline-rich andglycine-rich region likely located in the peptidoglycan. The 
C-terminal end is located within the cell wall and membrane (97). The consensus sequence of the PARF motif 
is depicted in a box that also indicates the N-terminal position of PARF in M proteins (59). 
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Long stretches of the M protein sequence contain heptad repeats. Due to the α-helical 
structure, the first (a) and fourth (d) amino acid of the heptad repeat within an M protein chain 
are able to form hydrophobic bonds with their counterparts on the homologous M protein 
chain. The fifth (e) and seventh (g) amino acid form ionic interchain bonds (Fig. 7).  
 
Figure 7: Schematic representation of the interactions that occur in an M protein coiled-coil. Position a and 
d are occupied by hydrophobic amino acids, b-c-f are polar amino acids, e-g are charged amino acids. 
These interactions of core residues within the coiled-coil are important for the stability of the 
coiled-coil structure (98). The continuity of the heptad pattern is often disrupted because of 
insertion of additional amino acid residues, suggesting that M proteins have a flexible coiled-
coil structure. The biological relevance of these irregularities is unknown, but they are also 
characteristic for coiled-coil proteins of eukaryotic origin, such as myosin and tropomyosin 
(99). Structural irregularities that occur in myosin and tropomyosin as well as in the M1 
protein seem to be involved in evoking the production of cross-reactive antibodies by 
molecular mimicry. This may explain some of the autoantibody titers seen in patients with 
streptococcal autoimmune sequelae (98, 1.7.2 ARF and RHD). 
The N-terminal hypervariability of the M protein results in antigenic variation (28-100) and 
is exploited for serotyping and, on the DNA level, for emm-typing (1.5 Emm-typing). 
Moreover, the N-terminal part of M protein elicits the production of type-specific protective 
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antibodies and is therefore considered as a valuable S. pyogenes vaccine candidate (1.8.2 M 
protein based vaccines). 
Depending on the emm-type, the N-terminus of the M protein harbours the peptide associated 
with rheumatic fever (PARF) (Fig.6), a binding site for collagen IV. M proteins with a PARF 
motif triggered collagen IV autoimmune responses in mice, suggesting that the motif could 
take part in eliciting rheumatogenic processes (59-101-102). The role of the PARF-motif in 
inducing ARF-related autoimmune responses is further investigated in this work. 
The hypervariable N-terminal sequence of M protein can contain A-repeats and is followed by 
the variable region that includes the B-repeats (Fig. 6). The B-repeats bind human fibrinogen, 
contributing to the antiphagocytic property of M protein (103). In some M proteins such as 
M1, M55 or stG11 the B-repeats are followed by the S-region, which binds human 
immunoglobulin G (IgG) in a non-immune fashion, via the Fc region of the IgG (104-105-
106). Efficient bacterial IgGFc-binding by M protein occurs only in IgG-poor environments, 
such as saliva, and protects streptococci against phagocytic killing (107). In blood plasma, 
where the concentration of IgG is high, the antibodies bind M proteins mainly via Fab, which 
facilitates opsonization and bacterial killing. IgG-poor environments represent the natural 
habitat for IgGFc-binding bacteria and IgGFc-binding proteins may have evolved to exert 
their function in such environments. The lack of protection in plasma also helps to explain 
why cases of severe invasive infections with IgGFc-binding bacteria are so rare compared 
with more superficial and uncomplicated infections of the throat and skin (106). 
The C-terminal region, well conserved between M proteins of different emm-types, is 
composed of the C- and D-repeats and the LPXTG-motif, which is followed by a sequence of 
wall-associated amino acids. This terminal wall-associated part of the M protein sequence is 
divided into two regions, one that is rich in proline and glycine. The other region is a 
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membrane anchor that consists of 19 hydrophobic amino acids (79). The M protein ends with 
a C-terminal sequence of six charged amino acids of unknown function. During the 
maturation of the M protein, a sortase catalyzes the cleavage between Thr and Gly of the 
LPXTG consensus motif and covalent binding to the streptococcal peptidoglycan wall (107). 
The LPXTG consensus motif is highly conserved in surface proteins of streptococci and other 
Gram-positive bacteria (107). 
1.6.1.2 Functions of the M protein and its role in pathogenesis 
The M protein is an adhesin, antiphagocytic factor and potent trigger of inflammation of S. 
pyogenes that contributes to the virulence and pathogenicity of this bacterium (28). 
Adhesion of bacteria to dermal tissue or mucous membranes is an initial and crucial step in 
establishing streptococcal infection in the host. S. pyogenes expresses a panel of adhesion 
factors that bind strongly to host tissue components to counteract removal by protective host 
mechanisms such as the flow of saliva or blood. Different streptococcal genotypes can 
express an individual set of adhesins that interact with specific targets in the host. This 
depends on the strain’s genetic makeup and its regulation of gene expression (108). 
The C-terminus of the M protein binds several host molecules like the complement regulator 
factor H (109) and human serum albumin (102-105-110-111) promoting the virulence and 
the persistence of S. pyogenes in the host (112). Moreover, some M proteins exert adhesin 
properties by binding to several collagen types (113) or to gylcosaminoglicans (GAGs) 
(114). These interactions attach the streptococci to the extracellular matrix of the host or to 
cells such as human epithelial cells and skin fibroblasts (115). 
M protein promotes the aggregation of S. pyogenes. The aggregation is mediated by a 19 
amino acid long segment in the B-repeat region of M1 protein (116). This mechanism 
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increases resistance to phagocytosis and is involved in adherence to and invasion into 
epithelial cells, thereby contributing to the virulence of S. pyogenes (116). 
Many M proteins interact with the complement regulator C4b-binding protein (C4BP), which 
inhibits the classical pathway of the complement system under non-immune conditions and 
may protect streptococci against phagocytosis (117-118-119). Other M proteins act as 
antiphagocytic factors by binding to fibrinogen (120), such as M1 protein that binds 
fibrinogen via the B-repeats (121, 1.7.1.1). This interaction diminishes covalent binding of 
the C3 convertase of the complement system on the streptococcal surface, resulting in reduced 
cleavage of C3 into C3a and C3b. C3a is an anaphylatoxin that attracts and stimulates 
immune cells (122). The C3b opsonizes S. pyogenes for phagocytes that harbour the C3 
receptor. Hence, interfering with C3b deposition by binding fibrinogen reduces phagocytosis 
(103). 
In addition, M protein, released from the streptococcal surface, forms complexes with 
fibrinogen. These aggregates activate neutrophils by binding to β2-integrin of these cells. As a 
result, neutrophils release heparin binding protein, an inflammatory mediator that induces 
vascular leakage. In mice, injection of M protein or subcutaneous infection with S. pyogenes 
causes severe pulmonary damage characterized by leakage of plasma and blood cells, which 
resembles the pathology of STSS (123). Moreover, M protein/fibrinogen complexes were 
identified in tissue biopsies from a patient with necrotizing fasciitis and STSS, further 
underlining the pathogenic significance of such complexes in severe streptococcal infections 
(124). 
Invasive S. pyogenes infections cause severe systemic inflammatory reactions and 
complications such as sepsis (28-124). Important triggers of inflammation include 
streptococcal superantigens that evoke a strong cytokine production by activating T cells 
(124), streptolysin O that stimulates human neutrophils (125) and M protein (126). In 
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addition, M protein stimulates infiltrating monocytes/macrophages, inducing secretion of IL-
6, IL-1β and TNFα (126). Highly purified M1 protein induced T-cell proliferation and release 
of TNFβ and INFγ, triggering inflammatory processes (127). Taken together, the M protein 
contributes to local and systemic inflammatory reactions during streptococcal infections. 
In addition to their role in acute infection, M proteins are suspected triggers of ARF as 
described in paragraph 1.7.2. 
1.6.2 M-like proteins 
Approximately half of all S. pyogenes isolates have up to two genes that code for M-like 
proteins, the emm, the mrp and the enn genes (128-129-130-131). These genes are adjacent 
to the emm gene in the Mga region of the streptococcal chromosome and are under the control 
of the positive regulator Mga (multi gene activator) (132-133-134) (Fig. 3). The respective 
M-like proteins are referred to as M-related protein (Mrp) and Enn, which are 
immunologically dissimilar (135).  
Like some of the M proteins, Mrp is a streptococcal IgG-receptor that binds to the Fc region 
of the immunoglobulin. For this reason it is also named fcR (Fc receptor). As it binds to 
fibrinogen, like M proteins, it is considered as an antiphagocytic factor (136). Moreover, the 
co-operation of M proteins and Mrp contributes to phagocytosis resistance by decreasing 
streptococcal binding to granulocytes (136). 
The majority of enn genes encode proteins that bind IgA (137). In vitro the enn gene is 
transcribed at a very low level when compared to the emm and mrp genes, or not at all (137-
138-139). However, the expression of emm, mrp and enn gene products can vary depending 
on infection sites and may be part of the bacterial strategy to evade the immune system and 
colonize the host (137).  
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Studies on emm, enn and mrp deletion mutants showed an increased sensitivity to 
phagocytosis as compared to the wild type strain (140). These data suggested a functional 
redundance among M and M-like proteins that provides resistance against phagocytosis 
(141). An extensive knowledge about the role of Mrp and Enn in pathogenesis is missing. 
A study on streptococci of emm-type 18 identified a surface protein called “streptococcal 
protective antigen” (Spa18), (142). This emm-type was responsible for an endemic outbreak 
of S. pyogenes infections that led to ARF (143). An analogous investigation on streptococci 
of emm-type 36 identified the allelic variant Spa36 (143). Spa18 and 36 share characteristics 
with M-like proteins, but the spa gene that codes for these proteins is not located in the Mga 
region. Like the M proteins and the M-like proteins Mrp and Enn, Spa proteins are 
hypervariable in their N-terminal sequence and the C-terminus is conserved. Spa proteins 
Spa18 and 36 are up to 95% identical to the M-like protein of S. equi subsp. zooepidemicus 
suggesting horizontal transfer of the gene to S. pyogenes (65). Secondary structure prediction 
using Paircoils2 identified a long central coiled-coil region in Spa (65). Spa18 is located on 
the streptococcal surface and together with the M protein contributes to the virulence of 
streptococci by acting against phagocytosis (141-143-144-145). In conclusion, M-like 
proteins Mrp, Enn and Spa represent a class of streptococcal proteins that share structural and 
functional homologies with the M protein. Similar to M proteins, they may have a role in 
ARF, which remains to be investigated. 
1.7 Streptococcal autoimmune sequelae  
1.7.1 Poststreptococcal glomerulonephritis  
Poststreptococcal glomerulonephritis (PSGN) is an immune sequela that appears with a delay 
of 1 to 3 weeks after infection by S. pyogenes or S. equi subsp. zooepidemicus. This disease 
occurs primarily in children, young adults and individuals over the age of 40 years (146). 
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PSGN is associated with pyoderma in tropical climates throughout the year and in temperate 
climates during the summer season (147). Alternatively, during cold seasons PSGN is 
associated with throat infection in regions with temperate climate (146). Crowding and poor 
hygiene promote PSGN outbreaks (148-149-150). Moreover, in S. pyogenes the 
nephritogenic potential seems to be linked to certain emm-types, which suggests a role of the 
M protein or other type specific factors in triggering PSGN (150). Early studies suggested 
shared epitopes between streptococci and glomeruli as trigger of the disease (152-153-154). 
However, an extensive review of the experiments reporting cross-reactivity between 
mammalian tissues and streptococci concluded that most of the preparations used in these 
studies were likely to contain streptococcal IgG receptors or tissue IgG Fc receptors (155), 
which invalidated the hypothesis of molecular mimicry.  
Histopathological examination of afflicted glomeruli revealed characteristic structures called 
sub-epithelial ‘‘humps’’ on the luminal site of the glomerular capillary basement membrane. 
Streptococcal antigens, complement factors and immunoglobulin are localized in these humps 
(156-157). This supports the notion of immune-mediated mechanisms in the pathogenesis of 
PSGN (158). In fact, circulating immune complexes containing streptococcal antigens were 
found in 58% of patients with PSGN (158-159). Interestingly intact S. pyogenes was never 
found in glomeruli of patients with PSGN (160). 
Of the variety of potential nephritogenic factors that have been under investigation, so far 
there is none that can be considered as the sole nephritogenic factor. Despite the fact that 
many of the suspected nephritogens accumulate in the kidney of laboratory animals, leading 
to glomerular injury, none of these factors alone was capable to evoke a disorder that 
resembled PSGN sufficiently. The repertoire of host pathogen interactions that leads to PSGN 
is not yet uncovered and the molecular pathogenesis of PSGN is still widely elusive. 
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1.7.2 Acute rheumatic fever and rheumatic heart disease 
1.7.2.1 Epidemiology of ARF and RHD 
Acute rheumatic fever (ARF) is an immune sequela of insufficiently treated streptococcal sore 
throat that can lead to rheumatic heart disease (RHD). Most of the patients with ARF are 
children, adolescents or young adults. More than 500.000 new cases of ARF occur every year 
(26). RHD has a prevalence of at least 15 million cases worldwide, with 282 000 new cases 
each year (26). ARF and RHD are responsible for about 200.000 deaths every year. Some 
geographic regions e.g. Sub-Saharan Africa, South central Asia and some communities of 
Indigenous Australians are particularly affected by a high prevalence of ARF/RHD (28-50-
159). 95% of the estimated deaths caused by ARF or RHD occur in these regions (26), where 
RHD remains the major acquired cardiologic disease in the young and middle age population 
(26). Prevalence of ARF and RHD is high among people that live under low socioeconomic 
conditions and have poor access to medical care. Moreover, certain humans appear 
genetically predisposed to ARF as shown by association with certain HLA types (28). 
However, the value of the HLA type as a prognostic marker for ARF is not clear (161). 
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1.7.2.2 Pathology of ARF 
ARF occurs with a latency period of 1–4 weeks (162). The diagnostic criteria for ARF are 
known as the Jones criteria, which comprise 
Major Jones criteria: 
 Carditis (murmur, cardiomegaly, pericarditis, and congestive heart failure) 
 Erythema marginatum 
 Migratory large joint polyarthritis 
 Sydenham chorea 
 Subcutaneous nodules 
Minor Jones criteria: 
 A previous history of rheumatic fever 
 Arthralgia 
 Fever 
Positive diagnosis of rheumatic fever is made when at least two major or one major and two 
minor Jones criteria are met (163). This diagnosis is strongly supported by evidence of a 
preceding streptococcal infection, e.g. elevated antibody titers against streptococcal antigens 
like streptolysin O. About a third of the ARF patients develop RHD, leading to irreversible 
damage of the heart valves (159). These patients require surgical intervention and often 
substitution of the heart valves. 
Histopathologically, ARF is characterized by inflammatory changes in the extracellular 
matrix or subendothelial and perivascular tissue (164-165). Granuloma formation comprising 
perivascular Aschoff nodules has been described as the most-characteristic finding in 
rheumatic carditis (166-167). The depth of perivascular inflammation is limited and 
interstitium beyond this area appears normal. In almost all patients with ARF the pericardium 
is affected. The myocardium is often spared (164) and no residual damage in myocardium or 
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pericardium is observed after the acute episode of rheumatic fever is resolved (164). In 
contrast, the valvular tissue sustains permanent damage after active carditis (164). The mitral 
valve is most frequently affected (167), followed by the aortic valve that is frequently 
inflamed (164). 
In conclusion, ARF pathogenesis suggests that the primary site of damage is the 
subendothelial and perivascular extracellular matrix (166). 
1.7.2.3 Pathogenesis of ARF 
Elevated autoantibody titers in the sera of ARF/RHD patients (101-113-162) and deposition 
of immunoglobulin and complement in the affected hearts (168) indicate that humoral 
immunity is involved in ARF pathogenesis. The early processes in rheumatic carditis involve 
cellular immune responses as indicated by the high number of T-lymphocytes and 
macrophages that occur in the cellular infiltrates observed in myocardial lesions of affected 
hearts (169-170-171). Moreover, the inflammation that takes place in those patients is 
characterized by increased numbers of mature circulating T helper cells (170), elevated levels 
of cytokines such as IL-1 and IL-2, IFN-γ, TNF-α and higher amounts of receptors for these 
cytokines (170). Autoimmune responses against several host proteins such as cardiac myosin, 
heart valve glycoproteins, antigens of the sarcolemma membrane and collagen occur in ARF 
or RHD patients (101-170-172-173). These observations suggest that ARF is caused by 
detrimental immune responses and inflammation that are not sufficiently suppressed after 
infections caused by S. pyogenes. 
1.7.2.4 Streptococcal factors in ARF 
The molecular and immunological processes that could drive the pathogenesis of ARF and 
subsequent RHD have been partially discovered. (101-170-174). Streptococcal factors such 
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as streptococcal superantigens, group A carbohydrate, hyaluronic acid capsule and M proteins 
have been suspected to trigger the autoimmunity that is seen in ARF. The role of these 
bacterial components in the induction of ARF is described below.  
1.7.2.4.1 Superantigens in ARF 
During acute infection, streptococcal superantigens contribute to virulence by activation of T 
cells and induction of strong inflammatory responses (175-176-177). Superantigens bridge 
the MHC class II of the antigen presenting cells with the T-cell receptor, which activates the 
T-cells that carry a matching T-cells receptor V-beta region. These T-cell populations will 
release pro-inflammatory cytokines. Furthermore, interaction of coreceptors CD28 or LFA-1 
on T-cells with the ligands B7 or ICAM-1 on antigen presenting cells, stimulate a polyclonal 
expansion of the activated T-cells. In the absence of these co-stimulating interactions, the 
activated T-cells fall into anergy or apoptosis (146), resulting in the selection for a certain T 
cell population. It has been speculated that if the mitogenic activity induced by superantigens 
is combined with a break of tolerance, the patient may produce auto-reactive cells (176-178). 
In this case, superantigens may play a role in the autoimmune processes seen in ARF 
pathogenesis that remains to be further investigated. 
1.7.2.4.2 Group A carbohydrate in ARF 
Crossreactivity of autoantibodies from ARF patients with streptococcal cell wall 
carbohydrates, the cell membrane or the M protein was demonstrated in different studies 
(179-180). Therefore, monoclonal antibodies (mAbs) have been used to characterize the 
crossreactivity between streptococci and the host proteins, which contributed to the 
understanding of the pathogenesis of rheumatic heart disease. Monoclonal antibodies against 
N-acetyl-beta-d-glucosamine (GlcNAc), the immunodominant epitope of group A 
carbohydrate, have been detected in patients with rheumatic valvular disease suggesting their 
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role in the pathogenesis (181). Notably, GlcNAc is ubiquitous in the host’s extracellular 
matrix and shares epitopes with the streptococcal group A carbohydrate that contains the same 
monosaccharide unit (171). Thus, autoimmune responses against GlcNAc of the group A 
carbohydrate may be causative for the early, less specific symptoms in ARF (159). 
1.7.2.4.3 Role of hyaluronic acid in ARF 
Hyaluronic acid is produced by the bacteria as well as it is abundant in the host’s extracellular 
matrix. S. pyogenes M18, an isolate that is highly encapsulated with hyaluronic acid, caused 
two outbreaks of ARF in Utah, USA (182). Hence, the S. pyogenes capsule was suspected to 
cause autoimmunity. More recent work suggests that the hyaluronic acid capsule binds and 
aggregates collagen on the streptococcal surface, which could evoke the production of 
collagen autoantibodies similar to what has been observed for M protein (1.7.2) (113). 
However, isolated hyaluronic acid alone seems not sufficient to trigger disease, since it is 
widely used in cosmetic medicine with a low risk for immune complications.  
1.7.2.5 Role of M protein in ARF 
1.7.2.5.1 M protein and molecular mimicry  
M proteins form dimers via long α-helical coiled-coil regions. Coiled-coil structures are also 
found in several host proteins such as α-keratin, human heart myosin and laminin. This 
structural similarity between host molecules and the M protein is the cause of immunological 
crossreactivity known as molecular mimicry (183). Molecular mimicry is considered as one 
of the triggers of the detrimental immune responses in ARF (174-184). The blood of 
ARF/RHD patients contains higher concentrations of these cross-reactive antibodies as 
compared to healthy individuals (185). Notably, the autoantibodies from ARF patients differ 
in reactivity from anti-cardiac antibodies seen in heart failure or postcardiotomy patients, 
which are a sequel of cardiac damage (186). This suggests that the autoimmunity in ARF is 
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the cause for the cardiologic symptoms. Monoclonal antibodies derived from ARF/RHD 
patients were poly-reactive to M protein, human coiled-coil proteins and GlcNAc (28). 
Human myosin cross-reactive antibodies recognize epitopes in M proteins M5, 6 and 19 
(187-188) and appear to contribute to the pathogenesis of carditis in ARF (28). Therefore, 
molecular mimicry between streptococcal M protein and host tissue is considered as one of 
the initiating mechanisms of this disease. In addition, T-cells isolated from severe cases of 
RHD cross-recognized M5 peptides, heart tissue proteins and myosin peptides. This 
stimulates the T cells to produce high amounts of inflammatory cytokines and low levels of 
IL-4, suggesting that mimicry between streptococcal antigens and heart-tissue proteins, 
combined with high inflammatory cytokine and low IL-4 production, leads to the 
development of autoimmune reactions and cardiac tissue damage in RHD patients (189). 
Taken together these experimental data indicate molecular mimicry as one cause for 
autoimmunity that leads to ARF (174-184). 
1.7.2.5.2 M protein, PARF and collagen binding as a trigger of ARF 
An alternative mechanism of triggering autoimmune responses that are observed in ARF 
involves the M protein’s ability to induce autoimmune response against collagen IV (101-
102 113). The M3 protein (190) that caused ARF and ARF-like symptoms in vaccinees 
(71), binds collagen to the streptococcal surface and causes its aggregation (113). This 
interaction, which occurs with collagen of types I–IV, has been observed in different types of 
M protein including M proteins of SDSE and it depends on an octapeptide motif located in the 
N-terminal hypervariable part of the M protein (Fig. 6) (59-101-102). This motif contributes 
to acute infections by facilitating streptococcal colonization of the extracellular matrix (113). 
M3 protein and other collagen-binding M proteins that carry the PARF motif trigger 
production of anti-collagen IV antibodies. Therefore, it has been suggested that induction of 
collagen autoimmunity requires the binding of M protein to collagen. Detrimental 
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autoimmunity against collagen may initiate the inflammation seen in ARF. Collagen IV is a 
major component of basement membranes and is localized beneath the endothelium that 
covers the heart valves. Thus, it could be one of the target of the autoimmune responses that 
lead to valvular damage. This hypothesis is supported by the fact that anti-collagen IV 
autoantibodies were also found in increased levels in ARF and RHD patients as compared to 
healthy individuals (101-113). For this reason, the collagen binding motif was named PARF, 
as an abbreviation of peptide associated with rheumatic fever (101). The increase in collagen 
IV autoimmunity occurs early during acute pharyngitis before the onset of ARF, which 
indicates that the anti-collagen IV immune response is causative for the sequelae rather than a 
consequence of the tissue destruction seen in ARF and RHD (113). 
Different from the myosin-directed autoimmunity, collagen IV autoantibodies produced in 
response to PARF positive M proteins do not cross-react with the M protein, suggesting that 
the immune reactions against collagen in ARF/RHD are not caused by molecular mimicry. 
The binding of M protein to collagen may alter the presentation of the autoantigen, leading to 
a break of tolerance (101-113). The detailed pathomechanisms, however, remains elusive. 
The PARF-dependent collagen autoimmunity may be a ‘‘conformeropathy’’ analogous to the 
Goodpasture’s syndrome. In Goodpasture’s syndrome, a conformational change in the non-
collagenous domain of collagen IV leads to exposure of epitopes that evokes the production 
autoantibodies against the glomerular basement membrane. This causes a collagen IV 
autoimmune disease that affects the lungs and kidneys (191-192). 
The S. pyogenes of emm-type 3, which harbour PARF, represent 7% of the S. pyogenes 
isolates from human infections world-wide (193-194) which underlines their clinical 
relevance.  
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Although the PARF motif binds to a variety of collagens, e.g. collagens I and IV, not all the 
PARF-containing M proteins bind collagen with high affinity (59). This creates an 
opportunity to investigate the role of PARF and its ability to bind collagen in triggering the 
collagen autoimmune response. This can for the first time shed light on the role of a protein 
interaction in induction of autoimmunity. 
S. pyogenes possesses several collagen-binding proteins that do not belong to the M- or M-
like proteins. The protein Cpa (collagen-binding protein of group A streptococci) that bound 
to collagen type I, was identified in about 30% of 68 different S. pyogenes serotypes (195). In 
addition, the streptococcal leucine rich (Slr) protein, an abundant membrane bound 
lipoprotein, is co-expressed on the bacterial surface with M1 and was shown to be involved in 
the interaction with collagen type I (196). However, the role collagen binding proteins like 
Cpa and Slr in triggering collagen autoimmunity remains unexplored.  
1.7.3 Role of S. dysgalactiae subsp. equisimilis in ARF 
SDSE is a major human pathogen of the GCGS (197-198). Moreover, there are convincing 
indications that infection with SDSE can cause ARF (1.4 SDSE), which is challenging the 
previous picture of the etiology of ARF.  
The vast majority of SDSE strains that colonize or infect humans have M proteins like S. 
pyogenes. This explains why pharyngeal SDSE isolates from a community of Indigenous 
Australians evoked anti-myosin responses in mice. Most likely, this is reflecting a 
rheumatogenic potential of SDSE strains that is responsible for the high prevalence of ARF in 
this community (44). More than 10% of clinical SDSE isolates collected in Southern India 
bore collagen-binding M proteins. This region is also known to suffer from a high prevalence 
of ARF (59) as well as high rates of SDSE throat carriage and pharyngitis (199). Taken 
together, SDSE carry the factors that trigger ARF-associated autoimmunity. Although the 
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relevance of SDSE in ARF requires further examinations, these bacteria must not be 
neglected in the medical practice and in research as potential cause of ARF. 
1.7.4 Outlook 
Discovering the factors and the molecular mechanisms by which streptococci trigger 
autoimmune sequelae will help to combat this significant threat to human health. The 
identification of streptococci with a nephritogenic or rheumatogenic potential could facilitate 
identification of patients who are at high risk of contracting these immune diseases and who 
benefit from an intensified preventive treatment. Moreover, increasing knowledge on 
rheumatogenic streptococci and their rheumatogenic factors may have a substantial impact on 
the design of vaccines that aim at preventing the infections and their autoimmune sequelae. 
Future vaccines may have to protect against a broader range of streptococci that includes 
SDSE.  
1.8 Vaccines against S. pyogenes 
The substantial impact of S. pyogenes on human health has motivated more than half a 
century of search for a vaccine against this pathogen. Although several S. pyogenes vaccine 
formulations elicit protective immunity in animal models and have shown promising results in 
early-stage human trials, a safe and effective vaccine against S. pyogenes for use in humans is 
not yet available (28-200).  
In order to develop a vaccine that covers a broad variety, if not all S. pyogenes bacteria, 
several antigens have been investigated as potential vaccine candidates. However, several 
obstacles were encountered during the development of such a vaccine.  
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As described in paragraph 1.5, emm-typing studies shed light on the diversity and the regional 
and temporal variation of circulating S. pyogenes genotypes (78). The corresponding high 
antigenic diversity of S. pyogenes reduces the number of conserved protective antigens and is 
one of the obstacles in vaccine development. Several approaches have been adopted to 
overcome this problem. These approaches include the design of multivalent vaccines that 
incorporate several streptococcal antigens or the design of vaccines that target the circulating 
strains of a specific geographic region (200). 
The development of a vaccine is further complicated by serotype replacement. For instance, 
the replacement of type emm1 by emm6 was observed under the pressure of protective 
immunity against emm1 within a short period of time (78). This indicates that a vaccine that 
targets only a few serotypes could be effective just for a short period of time, after which new 
serotypes could replace the types that are covered by the vaccine. 
As natural streptococcal infections or preparations of streptococcal antigens cause ARF, 
streptococcal vaccines are associated with a risk of induction of one of the diseases that they 
should prevent (27, 1.8.2). This problem goes alongside with the lack of animal models that 
allow to foresee the immune side effects of the vaccine (65). 
While facing these obstacles, vaccinology has followed two strategies in the development of 
S. pyogenes vaccines: M-protein-based vaccines and non-M protein based vaccines.  
1.8.1 Non-M protein based vaccines 
Because the M protein is suspected to trigger autoimmune side effects, research moved 
towards the design of non-M protein based vaccines (71, 1.6.1). The aim of this research is to 
find a safe vaccine formulation that is effective against a broad variety if not all S. pyogenes 
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bacteria. Some examples of these S. pyogenes vaccine candidates are described in this 
chapter. 
1.8.1.1 Group A carbohydrate  
As all known isolates of S. pyogenes carry the Lancefield group A carbohydrate (GAC) on 
their surface, this macromolecule was one of the first isolated antigens that were studied for 
use in a streptococcal vaccine. Anti-GAC antibodies opsonized S. pyogenes and protected 
immunized mice against challenge with S. pyogenes of different serotypes (201-202). 
However, immunological crossreactivity between anti-GAC antibodies with host proteins of 
the heart valve and the cytoskeleton, such as actin, keratin, myosin and vimentin (174) 
prevent the use of GAC as a S. pyogenes vaccine constituent. (200-203). 
1.8.1.2 Streptococcal protective antigen  
A more recent vaccine candidate is the M-like protein streptococcal protective antigen (Spa) 
(1.6.2). Spa elicited bactericidal antibody responses in animals (141-143). Spa-specific 
antiserum reacted with Spa or Spa-like proteins on streptococci of 25 out of 70 different emm-
types, suggesting that the recognized epitopes are conserved among a variety of S. pyogenes 
isolates (143). An N-terminal fragment of Spa is a component of the 26-valent M protein 
based vaccine named StrepAvax
TM
 (ID Biomedical Corporation, Canada), which has 
completed a phase II clinical trial and of the successor 30-valent vaccine, which is currently in 
a preclinical phase (1.8.2). 
1.8.1.3 Streptococcal cysteine proteinase A  
Streptococcal cysteine proteinase A (SCPA) is a sortase-anchored surface protein of S. 
pyogenes. This enzyme is also referred to as C5a peptidase as it cleaves the anaphylatoxin 
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C5a of the complement cascade, acting as an anti-phagocytic factor (204-205). Thereby, it 
promotes the virulence of streptococci (206). Homologous C5ase enzymes are also produced 
by streptococci of groups B, C and G, indicating that a SCPA vaccine could cross-protect 
against infections with these β-hemolytic streptococci as well (207). An injectable 
formulation of SCPA facilitated clearance of intranasally inoculated S. pyogenes in mice 
(208). A SCPA-based vaccine could cover the great majority of S. pyogenes strains as this 
antigen is carried by most, if not all isolates (209). Moreover, as SCPA has not yet been 
implicated in the induction of autoimmunity, it remains a promising vaccine candidate (210). 
1.8.1.4 Streptococcal superantigens 
A streptococcal vaccine that uses inactivated streptococcal superantigens SpeA or SpeC, 
evoked neutralizing antibody responses against these toxins. These responses protected 
rabbits against the toxic effect of the respective isolated superantigen (211-212). During 
acute streptococcal infection, immune responses against these superantigens may protect also 
humans from the toxic effects of the secreted superantigens, but the immune response may be 
non-bactericidal. In fact, toxin specific IgG responses may not be sufficient to opsonize the 
pathogen and prevent the adaptive immune responses against S. pyogenes that lead to ARF. 
Moreover, although it has been speculated about a role of superantigens in the induction of 
ARF (213), there are no experimental indications that they trigger autoimmunity (214-215) 
and their role in ARF pathogenesis is not sufficiently investigated.  
1.8.2 M protein based vaccines 
M protein based vaccines strive to exploit immune responses against this streptococcal cell 
wall-anchored protein. This is motivated by the protectivity of these responses in animal 
models of acute infection, as well as evidence for their protectivity in humans (216). 
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1.8.2.1 Potential risks associated with M protein vaccines 
Immunizing healthy human volunteers with preparations of the M protein decreased their 
colonization with life S. pyogenes after pharyngeal challenge (217). However, M3 protein of 
S. pyogenes, caused ARF or ARF-like symptoms in three out of 21 vaccinated children in 
early trials in the late 1960s (71), significantly more than in the untreated population. The 
potential of this antigen to cause autoimmune side effects in children underscores the role of 
full-length M proteins as triggers of autoimmunity. 
Several studies identified similarities in the coiled-coil structure of both M protein and myosin 
and suggested this molecular mimicry as the trigger of autoimmunity (169-189). Thus, a risk 
factor in M protein based vaccines. The myosin crossreactive sequence (Gln–Lys–Ser–Lys–
Gln) was identified in M5 and M6 proteins and shown to be located near the pepsin cleavage 
site (188), after amino acid 228, in the B5 repeat of the M protein (79). Moreover, other 
myosin crossreactive sites were identified in M5 (217) and M19 (187). Using overlapping 
synthetic peptides of M5 protein, myosin crossreactive B-cell epitopes were identified in 
peptides from the A, B and C repeat regions of M5 protein (218). Several approaches have 
been taken to exclude such parts from M protein based vaccine that could be the cause for 
immunological side effects. On the way to develop a safe vaccine it will be important to 
identify and exclude other rheumatogenic parts of the M protein. One of the possible 
rheumatogenic parts of the M protein is the PARF motif (101, 1.6.1). 
1.8.2.2 N-terminal M protein based vaccines 
One of the most promising vaccine candidates is based on the N-terminal hypervariable 
region of the M protein, a 26-valent vaccine named StrepAvax (219). This vaccine is 
composed of four different fusion proteins that contain six to seven N-terminal M protein 
fragments (50 amino acids) in a concatenated arrangement. The vaccine utilizes epitopes of M 
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proteins that evoke the production of bactericidal antibodies and that are less likely to cross-
react with human tissues (218). StrepAvax was designed to cover up to 26 different emm-
types, but it cross protected against other emm-types as well (220). The vaccine covers the 
predominant emm-types that caused invasive infections or ARF, in the USA and in Europe. In 
a human phase I clinical trial, StrepAvax evoked ex vivo bactericidal responses against all of 
the emm-types that were included in the vaccine (220). The vaccine did not produce ARF or 
ARF-like symptoms in 30 adult volunteers (220) despite the presence of PARF in the M3 
specific part of one of the vaccine antigens. 
Because ARF is mainly affecting children and adolescents, a vaccine against S. pyogenes 
needs to be safe for use in these age groups, which might react different from adults. Notably, 
the ARF-like symptoms that followed upon vaccination of 21 children with M3 protein, 
occurred only in children that were reinfected by streptococci (71). Thus, reinfection may be 
crucial for occurrence of the autoimmune side effects. As streptococcal pharyngitis is more 
frequent in children, they may have a higher risk to develop such side effects upon 
vaccination with StrepAvax (65). Data about the safety of StrepAvax from the phase II 
clinical trial on children are not yet available. 
With the aim of increasing the emm-type coverage, a 30-valent vaccine was designed and 
subjected to preclinical tests. This vaccine evoked bactericidal antibodies against 28 of the 30 
targeted emm-types in rabbit. Moreover, bactericidal cross-reactivity with 24 out of 40 non-
vaccine emm-types was observed, indicating that the actual emm-type coverage of this 
multivalent M protein vaccine is higher than its valence (221). Still, StrepAvax and the 30-
valent vaccine may cover the predominant emm-types that caused infections in the USA and 
in Europe but may not be sufficient to combat ARF/RHD in regions with a high prevalence of 
these diseases due to low emm-type coverage rates (222, 1.6.1). Furthermore, serotype 
 44 
 
replacement, observed in different regions of the world, may be a further threat to the success 
of these vaccine candidates.  
In addition, the multivalent vaccines include in their formula the N-terminal part of the M3 
protein, which contains the PARF motif. As this motif could to be involved in triggering 
rheumatogenic processes, the multivalent vaccines in their present form may be not safe. 
1.8.2.3 C-terminal M protein based vaccines 
Certain N-terminal parts of the M protein are suspected to trigger autoimmune reactions due 
to cross reactive epitopes, as explained in the paragraph 1.7.2 (Role of M protein in ARF). 
Therefore, research moved towards vaccines that use a more C-terminal part of the M protein 
that is conserved between different M-types, named conserved C-repeat region (CCR). Hence, 
the CCR could yield a better emm-type coverage as compared to peptides of the hypervariable 
part of M protein such as the peptides used in StrepAvax. Early studies showed that CCR 
derivative peptides were protective in mice that were challenged with S. pyogenes of different 
M types (223-224). 
One of the vaccines that exploits the CCR of the M protein is the StreptInCor vaccine (Fig. 8). 
This vaccine uses a peptide of 55 amino acids that combines a protective T-cell and B-cell 
epitope (225). StreptInCor induced high titers of specific antibodies as well as specific T-cell 
immune responses in mice. Immunized mice exhibited a high survival rate one month after 
challenge with S. pyogenes. Moreover, no cross-reaction to cardiac myosin was detected. 
Taken together, these data underline that StreptInCor could be an effective and safe vaccine 
for prevention of S. pyogenes infections (226-227-228). 
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Figure 8: Alignement of four CCR vaccines candidates, (names are given in bold on the left). The minimal 
common T-cell epitope is marked by a box (227-229-230-231). 
An alternative to StreptInCor is the 20 amino acid peptide within the CCR, named p145 
(229). Because a high proportion of people living in areas with high prevalence rates of ARF 
and RHD had increased titers of antibodies against p145 in their sera (232), this antigen has 
been investigated for use in a vaccine that could be protective against ARF and RHD. 
A derivative of p145 is the peptide J14. J14 is a part of p145 that contains a minimal T-cell 
epitope and carries heterologous flanking regions that preserve the α-helical structure of the 
internal M protein epitope, which is referred to as J14i (231). Vaccination with J14 protected 
mice that were challenged with S. pyogenes and led to production of bactericidal antibodies 
(233). J14i variants were identified in 77 different emm-types (234). The antigen SV1 that 
was composed of seven J14i modules of five J14i variants evoked production of bactericidal 
antibodies in mice (234). Moreover these antibodies were bactericidal against S. pyogenes 
serotypes that were not included in the vaccine in vitro (234). As for the multivalent N-
terminal M protein vaccines, despite promising preclinical testing, the available data do not 
yet fully exclude potential autoimmune side effects. However, due to the absence of known 
cross-reactive epitopes and lack of a PARF motif, such an antigen may be a favourable 
starting point for the development of a safe and effective vaccine against S. pyogenes. A 
further strength of the CCR-based vaccine as compared with StrepAvax is the use of less and 
similar antigen modules to cover the variety of S. pyogenes serotypes. A general CCR vaccine 
may be easier to design than an N-terminal M protein vaccine and bear a lower risk of 
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including rheumatogenic factors in the multivalent vaccine. Moreover, the risk of losing 
efficacy due to serotype replacement may be lower for CCR vaccines. 
1.8.3 Perspectives in development of a S. pyogenes vaccine 
Several vaccine candidates have been identified in the past and have shown promising results 
in preclinical models. Still, a vaccine that is protective against the acute infections and 
sequelae caused by S. pyogenes is not yet available and it cannot yet be foreseen when a 
streptococcal vaccine will be licensed. Major difficulties in the development of a vaccine are 
determined by the nature of streptococcal antigens used as vaccine candidates, as described in 
this chapter (1.8). However, the growing knowledge on these antigens and comprehensive 
identification of their noxious parts, which cause side effects, may contribute to guide the 
development of safe and effective vaccines against ARF. In addition to this, an important help 
to vaccine development against streptococcus can be given by reverse vaccinology (235). 
Reverse vaccinology is a new approach for vaccine development that aims to identify the 
complete repertoire of antigens that a pathogen expresses on its surface by screening of the 
whole genome sequence (236). This new approach can be of great help to find new protective 
streptocococcal antigens and contribute to the development of an effective streptococcal 
vaccine. 
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1.9 Aim of this study 
Previous studies indicated that the PARF motif is a possible player in triggering 
autoimmunity against collagen IV, an autoimmune response that occurs in ARF patients. It 
had not been studied if other motifs than PARF or other functions than collagen binding of the 
M protein are involved in triggering autoimmunity against collagen IV. Therefore, the aim of 
this study was to investigate the specificity of PARF as a trigger of collagen autoimmunity 
and the role of the collagen binding activity of PARF in this process. Different M proteins 
with and without PARF motif and differing in affinity for collagen IV should be produced 
recombinantly for this purpose and tested in a mouse model for induction of autoimmunity. 
Moreover, to test isolated PARF motifs, a synthetic peptide (peptide 17) that was optimized 
for collagen binding and recombinant protein that carried all known naturally occurring PARF 
motifs (PARF tandem) should be examined. As PARF tandem could be a useful vaccine 
antigen for immunization against PARF positive strains, one aim was to test its ability to 
evoke the production of opsonizing antibodies. PARF is present in about 7% of S. pyogenes 
isolates from human infections. In addition, other collagen binding factors may exist in these 
bacteria that trigger collagen IV autoimmunity. The role of Spa18, an M-like protein, in 
collagen binding and as a trigger of autoimmunity, should therefore be tested. Spa18 is 
present im emm18 strains of S. pyogenes, which have caused several outbreaks of ARF. 
The results should deliver new insights into the elicitation of autoimmunity by streptococcal 
proteins. 
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CHAPTER 2 
Materials and Methods 
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2.1 Buffers and solutions 
 Bicarbonate coating buffer: 0.1 M NaHCO3 in DI water adjusted to pH 9.0. 
 Luria-Bertani medium (LB): tryptone 10 g, yeast extract 5 g, NaCl 10 g in 1 L DI 
water.  
 Luria-Bertani agar (LA): LB plus 1.5% (wt/vol) agar. 
 Phosphate buffered saline (PBS): 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, 0.24 g 
of KH2PO4, in 1 L DI water, adjusted to pH 7.4. 
 PBST: PBS containing 0.05% (vol/vol) of Tween 20. 
 Super optimal broth with catabolite repression (S.O.C.): tryptone 20 g, yeast extract 5 
g, NaCl 0.5 g, KCl 0.18 g, MgCl2 0.95 g, glucose 3.6 g, in 1 L Milli-Q water, adjusted to 
pH 7.0. 
 Tryptic soy broth (TSB): tryptone 17.0 g, soytone 3.0 g, glucose 2.5 g, NaCl 5.0 g, 
K2HPO4 2.5 g, in 1L DI water, adjusted to pH 7.3. 
 TSS storage and transformation solution (TSS): LB with 10% (wt/vol) polyethylene 
glycol (PEG molecular weight 8000), 5% (vol/vol) dimethyl sulfoxide (DMSO) and 20-
50 mM Mg2+ (MgSO4), adjusted to pH 6.5. 
 Todd-Hewitt broth supplemented with 0.5% yeast extract (THY): heart infusion 3.1 
g, neopeptone 20.0 g, yeast extract 5.0 g, dextrose 2.0 g, NaCl 2.0 g, Na2HPO4 0.4 g, 
Na2CO3 2.5 g, in 1L DI water, adjusted to pH 7.8. 
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2.2 Ligation and Endonuclease digestion 
DNA ligations were performed using T4 DNA Ligase (Thermo Scientific) and following the 
manufacturer’s protocol. 
Endonuclease digestion of plasmids and PCR amplicons (25 µL) were performed using 1 µL 
FastDigest™ enzyme BamHI, SalI or EcoRV and 5 µL FastDigest™ Buffer (Thermo 
Scientific), in a volume of 50 µL for 1 h at 37°C. 1 μL of enzyme solution corresponds to 1 
FDU, which cleaves 1 μg of lambda DNA/Bsp120I fragments in 5 min at 37°C in 
FastDigest™ Buffer.  
2.3 Isolation and purification of the DNA 
PCR amplicons, plasmid and endonuclease digested DNA were isolated and purified with the 
NucleoSpin® Gel and PCR Clean-up Kit (Macheray-Nagel) following the manufacturer’s 
instructions. 
2.4 Preparation of competent cells 
Competent cells were prepared as described by Chung (237) with some modifications. Using 
a toothpick, E. coli cells were plated on LA containing antibiotics (100 μg/mL ampicillin for 
E. coli DH5-α or 100 μg/mL ampicillin and 25 μg/mL kanamicin for E. coli M15). Bacteria 
were incubated overnight at 37°C. On the following day, bacteria were inoculated in 10 mL of 
LB medium with antibiotics (see above LB cultures) and cultivated overnight at 37°C in a 
shaking incubator at 120 rpm. On the third day, 20 mL of culture was added to 200 mL of 
prewarmed TSS solution (2.1) until the bacteria reached the early exponential phase at an 
optical density (O.D.) of 0.3-0.4 at 600 nm wavelength. The bacteria were further cooled in 
ice for 10 min, centrifugated at 1000 x g for 10 min at 4°C and subsequently resuspended in 
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ice-cold TSS solution to one-tenth of the original volume. Aliquotes of 100 µL of bacteria in 
TSS were prepared in 1.5 mL Eppendorf Tubes®. The aliquots were quickly frozen in liquid 
nitrogen and stored at -80°C. 
2.5 Transformation of competent E. coli bacteria 
Aliquots of 100 μL of competent cells (E. coli M15 or DH5-α) were taken from -80°C and left 
for 5 min in ice. 1 μL of plasmid DNA, or 7 µL of ligation product were added and the 
bacteria were incubated on ice for further 30 min. After a heat shock step at 42ºC for 45 s in a 
water bath, the E. coli were incubated on ice for 10 min. Then, 300 μL of pre-warmed LB or 
S.O.C. medium without antibiotics was added and the bacteria were incubated at 37ºC for 1h 
in an incubator-shaker at 300 rpm. Finally, 200 μL of culture was plated onto pre-warmed LA 
with antibiotics (ampicillin 100 μg/mL) for DH5-α (ampicillin 100 μg/mL and kanamicin 25 
μg/mL) for E. coli M15 and incubated at 37ºC overnight. Positive clones were analyzed by 
colony PCR using the following conditions: 1 unit of Taq DNA Polymerase (Qiagen), 10 
pmol of primers 18 and 19 (Table 1), 1.25 mM MgCl2 and 0.04 mM of each dNTP in 20 μL 1 
x PCR Buffer (Qiagen). After initial denaturation (98°C, 30 s) and 25 cycles of denaturation 
(98°C, 10 s), annealing (55°C 30 s) and elongation (72°C, 2 min), final elongation was carried 
out at 72°C for 5 min. PCR products were analyzed by agarose gel electrophoresis (1% wt/vol 
agarose), stained with ethidium bromide and visualized using a Kodak Image Station 2000 
(Carestream Health). 
2.6 Generation of pQE30TEV expression plasmid 
Plasmid pQE30TEV, which codes for a TEV (Tobacco Etch Virus) protease recognition site 
C-terminal of a His6-Tag (Fig. 9), was produced by PCR using vector pQE30 (Qiagen) as 
template, 1 unit of Phusion® High-Fidelity DNA Polymerase (New England Biolabs), 10 
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pmol of primers 1 and 2 (Table 1) and 0.04 mM of each dNTP in 50 µL 1 x Phusion® HF 
Buffer. After initial denaturation (98°C, 30 s), 26 cycles of denaturation (98°C, 10 s), 
annealing (55°C 30 s) and elongation (72°C, 3 min), final elongation was carried out at 72°C 
for 10 min. PCR products were analyzed as described earlier. After ligation with T4 ligase 
(Thermo Scientific) the plasmid was cloned in E. coli DH5-α (Invitrogen). 
 
Figure 9: Schematic representation of the pQE30TEV vector map. The TEV coding sequence (green) was 
inserted by PCR in-frame to the histidine tag (red). Restriction sites are listed above the multicloning site (grey). 
The figure was adapted from Quiagen product details (238). 
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2.7 Recombinant expression and isolation of proteins 
Coding regions corresponding to the mature full length M proteins stG11, M1, M55, stG2078, 
M3.23, M3.0 and the M-like proteins Spa18 and Spa36 were amplified by PCR using specific 
primers 3 to 15 (Table 1) and the correspondent genomic DNA as template. The following 
PCR conditions were used: initial denaturation (98°C, 30 s), 25 cycles of denaturation (98°C, 
10 s), annealing (55°C, 30 s) and amplicon specific elongation (72°C) (Table 1). The obtained 
PCR products were ligated between the BamHI and SalI cleavage site of the pQE30TEV 
vector. For overexpression of M proteins, M-like proteins and PARF-tandem, E. coli M15 
pRep4 (Qiagen) were transformed with the produced plasmids and cultured in LB medium 
supplemented with ampicillin 100 μg/mL and kanamicin 25 μg/mL to an optical density of 
0.5 at 600 nm wavelength. Then, protein production was induced by adding 1 mM IPTG 
(Isopropyl β-D-thiogalactopyranoside) and the bacteria were further cultivated overnight at 
30°C. The bacteria were harvested by centrifugation (15 min; 18.000 × g), resuspended in 
LEW Buffer (Macherey-Nagel) containing protease inhibitor (cOmplete, Mini, EDTA-free, 
Roche) and homogenized using a French Press at 1000psi. Debris was removed from the 
lysate by centrifugation (20 min, 31.000 × g). Proteins were isolated from the lysate by 
affinity chromatography using Protino Ni-TED 2000 packed columns (Macherey-Nagel) 
following the manufacturer’s protocol (Fig. 10).  
 
Figure 10: Analysis of the affinity chromatography purification using a 12% SDS-PAGE. A molecular 
weight standard is indicated on the left in kDa. The lanes are assignes to the recombinant proteins in the box on 
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the right. The amino acid sequences of the recombinant proteins are given in FASTA format in the supplements 
section. 
Alternatively, the coding sequence of stG120.1 was used as template to amplify the truncated 
variants stG120.1s using primers 16 and 17, under conditions described in Table 1. After 
digestion with FastDigest™ EcoRV and subsequent ligation, the obtained plasmid 
pQE30TEV120.1s was cloned into E. coli. The protein StG120.1s that contained a His-tag 
was produced and purified as described above. StG11 1-A protein that contained a GST-tag 
was overexpressed in E. coli as described above and as in (101). The protein StG11 1-A was 
further purified by affinity chromatography using Glutathione-Sepharose 4B (GE Healthcare) 
and eluted with 10 mM reduced L-glutathione (Sigma-Aldrich) in 50 mM Tris-HCl (pH 8.0). 
All the isolated proteins were dyalized against PBS and stored at -20°C. 
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Reaction and Primers Sequence 5'-3' Elongation 
time [s] 
Production pQE30TEV 
  1 CACGGATCCGCATGCGAGC 180 
2 
GCGGATCCCTGAAAATACAGGTTTTCTCCGTGATGGTGA
TGGTGATGC 
 Amplification stG11 
  3 GCGGATCCGCGGAGAATACATACGATAGATGG 60 
4 GCTGTCGACTTATTAACCTGTTGATGGTAACTGTCTCTT 
 Amplification AP-1 
  5 GCGGATCCAACGGTGATGGTAATCCTAGGGAA 140 
4 GCTGTCGACTTATTAACCTGTTGATGGTAACTGTCTCTT 
 Amplification M3.0 or M3.23 
  6 GCGGATCCGATGCTAGGAGTGTTAATGGAGAG 90 
4 GCTGTCGACTTATTAACCTGTTGATGGTAACTGTCTCTT 
 Amplification M55 
  7 GGGGGATCCCAAACAGAACCATCTCAGACC  60 
4 GCTGTCGACTTATTAACCTGTTGATGGTAACTGTCTCTT 
 Amplification stG2078 
  8 GAAGTTGAATCCGCGGAGAATACATAC 90 
9 GACAAGATCATAATCTGCTTGTTT 
 Mutation PCR stg11AA 
  3 GCGGATCCGCGGAGAATACATACGATAGATGG 20 
10 CCGAGCATATTCACCTATACTATTATTCTGC 
 11 GGTGAATATGCTCGGGCTGCACAAAAACTTAATG 55 
4 GCTGTCGACTTATTAACCTGTTGATGGTAACTGTCTCTT 
 Amplification Spa18 
  12 GCGGATCCGATTCAGTAAGTGGATTAGAG 60 
13 GCTGTCGACTTATTACTCACCAGTAGATGGCAATTG 
 Amplification Spa36 
  14 GCGGATCCGAAGATAGGATAAATAGTGATATA 60 
15 GCTGTCGACTTATTACTCACCAGTAGATGGTAATTG 
 Truncation 120.1s 
 
150 
16 CCCGATATCTGAGTCGACCTGCAGCCAAGC 
 17 GCGATATCTTATTAAACGGCAAGCTGATAAATTTC 
 Colony PCR 
  
18 CCCGAAAAGTGCCACCTG 120 
19 GTTCTGAGGTCATTACTGG 
 Table 1: Oligonucleotides used in this study. 
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2.8 Site directed mutagenesis 
The coding sequence of stG11 was mutated by a two-step PCR-based method using plasmid 
pQE30TEV-stG11 as template. The first step consisted of two PCR reactions. One amplified 
the DNA template from position 1 to 176 of the stG11 coding region using the primers 3 and 
10 (Table 1). The other PCR introduced the mutation and amplified the fragment form 
position 163 to 1671 using primers 11 and 4 (Table 1). The two amplicons, purified with 
Nucleo Spin (Macherey-Nagel) and eluted in 30 µL NE Buffer, were mixed (2 µL of each 
amplicon solution) and used in the second step, an assembly PCR that amplified the mutated 
coding sequence of stG11AA (Fig. 11). In all three reactions, initial denaturation (98°C, 30 s) 
was followed by 25 cycles of denaturation (98°C, 10 s), annealing (55°C, 30 s) and amplicon 
specific elongation (72°C, Table 1). Elongation was carried out for 60 s in the assembly PCR. 
Final elongation was carried out at 72°C for 5 min. The PCR product was further digested 
with BamHI and SalI and cloned into the pQE30TEV vector as described above, yielding 
plasmid pQE30TEV-stG11AA. Subsequently, protein StG11AA was produced and isolated as 
described earlier. 
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Figure 11: Schematic representation of the site directed mutagenesis. stG11 gene (A) was used as a template 
to perform the PCR 1 and 2 (B). An assembly PCR (C) was performed using the amplicons of the PCR 1 and 2 
to introduce a substitution of four nucleotides in the coding region of the PARF motif of the stG11 gene (D). The 
site of the mutation YL to AA in the PARF motif is highlited in red. 
2.9 Construction of a 20-valent PARF tandem coding sequence 
A nucleotide sequence that codes for 20 different naturally occurring PARF sequences 
including three N- and four C-terminal flanking amino acids (PARF tandem, Fig. 12 A) was 
optimized for overexpression in E. coli using GenScript web tools and then chemically 
synthesized (supplements, table 2). The synthetic DNA was ligated into the vector pUC57 
between the BamHI and the SalI restriction site in order to obtain the plasmid pUC57-PARF-
tandem (GenScript, Piscataway, NJ). After multiplication of pUC57-PARF-tandem in E. coli 
DH5-α (Invitrogen) 0.1 ng of pUC57-PARF tandem was digested with BamHI and SalI. 
Subsequently, the PARF tandem coding sequence was cloned into the expression plasmid 
pQE30TEV between the BamHI and the SalI restriction sites. E. coli M15 pRep4 (Qiagen) 
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were transformed with the pQE30TEV-PARF-tandem and PARF-tandem was recombinantly 
expressed as described above (2.6, Fig. 12 B). 
A  
His6-Tev [zzz(A/T/E)XYLXX(L/F)Nzzzz]20 
 
B 
 
Figure 12: Schematic diagram of the 20 valent PARF tandem protein. A. The PARF motif consensus 
(conserved amino acids are given in bold) and  flanking amino acids (z) are given in square brackets. B. Emm-
types included in the PARF tandem construct are given in the boxes. 
2.10 Labeling of Proteins with 
125
Iodine 
Labeling of proteins was performed as described by Hunter and Greenwood (239), using the 
chloramine-T method. This method is based on the iodisation of tyrosine residues of a given 
protein. Protein was dissolved in PBS to a final concentration of 1 mg/mL, and 100 μL of the 
suspension was transferred to a siliconized tube. 0.25 mCi carrier-free 
125
iodine (Amersham) 
was added and the reaction was started by addition of 20 μL of chloramin-T (1 mg/mL in PB). 
After incubation at RT for 1 min, the reaction was stopped with 20 μL of sodiumdisulfite (1 
mg/mL in PBS). The solution was filled-up to 2.5 mL with PBST and excessive radioactivity 
was removed by filtration using a PD-10 gel filtration column (Amersham). Radioactively 
labeled protein was eluted with 3.5 mL PBST. 
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2.11 Testing bacteria for collagen binding 
Collagen I (from calf skin) and collagen IV (from human placenta) (Sigma-Aldrich) were 
labelled with radioactive iodine (
125
I) (Hartmann Analytic). Streptococci were grown 
overnight (37°C, 5% CO2) in TSB, washed and resuspended to a concentration of 10
8
 bacteria 
per mL in PBST. Bacterial suspensions (250 µL) were incubated for 45 min with 10 µL 
solution of 
125
I-labelled collagen (approximately 95 ng of 
125
I-collagen I or 45 ng of 
125
I-
collagen IV, equaling 100.000 counts per minute). Unbound collagen was removed by 
washing in 1 mL PBST before radioactivity of the pellet was quantified in a Wallac 1470 
Wizard gamma counter (PerkinElmer). 
2.12 Ligand blots 
Recombinant M proteins, PARF-tandem, (1, 0.5, 0.25, 0.125 µg) and Spa proteins (4, 2, 1, 
0.5, 0.25 µg) were spotted onto nitrocellulose membranes (0.2 µm pores, Bio-Rad). After 
incubation for 1h at room temperature in PBST containing 5% skim milk and three steps of 
washing with PBST, the membranes were incubated overnight with radiolabeled collagen I 
(5.7 µg) or collagen IV (2.9 µg) in 10 mL PBST. Finally, the blots were washed thrice with 
PBST, before bound collagen was visualized using radiographic Amersham Hyperfilm ECL 
(GE Healthcare). 
2.13 Biolayer interferometry 
Bio-layer interferometry (BLI) is a label-free technology to measure interactions of 
biomolecules. BLI is an optical analytical technique that analyzes the interference pattern of 
white light reflected from two surfaces: a layer of immobilized molecules on the biosensor tip 
and an internal reference layer. The binding between the layer of immobilized molecules on 
the biosensor tip surface and an analyte in solution determine a wavelength shift that 
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correlates with the change in thickness of the layer. Thereby, interactions between molecules 
are measured in real time and the method allows to determine rates of association and 
dissociation and the dissociation constant with high precision (240-241). 
Interactions between M proteins and collagen IV were measured using the BLI technology in 
an Octet® RED96 System (ForteBIO) at 25°C using PBS as running buffer. 2 mg of collagen 
IV in 1 mL PBS was biotinylated using EZ-link NHS-PEG12-Biotin (Thermo Scientific) 
following the manufacturer’s protocol. The biotinylated collagen was purified using a PD-10 
Desalting Column (GE Healthcare). Streptavidin coated biosensors (SA biosensors, 
ForteBIO) were pre-wet in PBS for 20 min. After a baseline step of 120 s in 200 µL PBS, the 
biosensors were transferred for 500 s into 200 µL solution of biotinylated collagen (30 
µg/mL) for ligand binding, which resulted in immobilization of 0.5 to 0.8 nm of collagen. 
Control SA biosensors were treated the same, except that they were incubated in 200 µL PBS 
during the ligand binding step. Unspecific binding sites were saturated by incubating the 
biosensors for 200 s in 200 µL PBS containing 1% bovine serum albumin (BSA). Association 
of M protein with collagen was measured for 500 s in 200 µL solution of M protein in PBS, 
followed by the measurement of dissociation in 200 µL PBS for 200 s. The interactions were 
measured consecutively at M protein concentrations of 40, 10 and 5 µg/mL. Biosensors were 
regenerated between the measurements by washing for 30 s with 0.01% SDS in water. Data 
were processed and evaluated using the Octet User Software version 7.0 (ForteBIO). After 
subtraction of nonspecific binding, apparent dissociation constants (KD) were calculated based 
on the Langmuir 1:1 binding model. 
2.14 Synthetic PARF peptides 
Previous work identified a synthetic PARF containing 15-mer peptide that was optimized for 
to collagen IV (peptide 17 GVYRRYLETLNDRFQ) (242). For further experiment the 
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peptide 17 and a scrambled control (peptide 18 GVYRDLTLERYNRFQ) were produced by 
the in house service platform at the HZI. The peptides were synthetized using an Activo-P11 
instrument and were coupled to an acetylated groupo in the N-terminal and an amide group in 
the C-terminal. The peptides were further purified with HPLC and stored at room 
temperature. 
2.15 In vivo experiments  
Permission for animal experiments was obtained from the Nds. Landesamt für 
Verbraucherschutz und Lebensmittelsicherheit (Az33.9-42502-05-11A170). Full-lenght M 
proteins and Spa18 were injected into the peritoneum of 7 weeks old female BALB/c mice. In 
groups of five mice, each mouse was given an emulsion of 25 µg M protein in 50 µL of sterile 
PBS (Amresco) and 50 µL of Freund’s incomplete adjuvant (Sigma-Aldrich) per dose at days 
1, 7, and 14. Mice of a control group received an emulsion of 50 µL of PBS and 50 µL of 
Freund’s incomplete adjuvant. The animals were monitored for any symptoms of disorders. 
At day 21 the mice were sacrificed by CO2 suffocation and serum samples were taken.  
Alternatively, PARF-tandem antigen was injected into the peritoneum of ten 8-week-old 
female BALB/c mice following the same protocol of immunization used for Spa18 and M 
proteins.  
For experiments with synthetic peptides, an emulsion of 50 µg of peptide 17 
(GVYRRYLETLNDRFQ) or peptide 18 (GVYRDLTLERYNRFQ) in 100 µL PBS and 100 
µL Freund’s incomplete adjuvant (Sigma-Aldrich) were injected into the peritoneum of 8 
weeks old female BALB/c and C3H mice in groups of ten. Mice of a control group received 
an emulsion of 100 µL of PBS and 100 µL of Freund’s incomplete adjuvant. 
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2.16 Human sera 
Fifteen human sera, six from healthy donors and nine from ARF patients were described in a 
previous study (113). Four sera were recently collected from ARF patients in Chandigarh in 
accord with the local regulations. ARF was diagnosed applying the Jones criteria (243). 
2.17 Enzyme-linked immunosorbent assay 
Anti-collagen IV antibody titers in murine and human sera were determined as described 
previously (101) with few modifications. 96-well plates (flat bottom, high binding capacity, 
Greiner Bio-One) were coated overnight at 4°C with 50 µL of anti-human collagen IV rabbit 
polyclonal antibody (Progen, Heidelberg, Germany) diluted 1:100 in 0.1 M NaHCO3 (pH 9.0) 
blocked with 2% BSA in PBST, and incubated with collagen IV (2 µg/mL in PBS) for 1 h at 
37°C. After washing with PBST, 50 µL triplicates of diluted mouse sera (1:50, 1:150, 1:300 
and 1:600), or human sera (1:50, 1:200, 1:800 and 1:3200) in PBS containing 1% BSA were 
added to the wells and incubated overnight at 4°C. After washing with PBST, bound 
antibodies were detected colorimetrically using horseradish peroxidase-coupled secondary 
antibodies goat anti-mouse IgG, Jackson Laboratories) or goat anti-human IgG Fc specific, 
(Sigma-Aldrich) and 2,2-azino-di-[3-ethylbenzthiazoline sulfonate] diammonium salt (ABTS, 
Roche Applied Science). The absorbance was measured at a wavelength of 405 nm in a 
Sunrise ELISA plate reader (Tecan). 
Alternatively, 96-well plates (were coated over night at 4°C with 2 µg/mL of collagen I (calf 
skin, Sigma-Aldrich), laminin (human placenta, Sigma-Aldrich), or myosin (calcium 
activated, porcine heart, Sigma-Aldrich), respectively in 50 µL PBS. The wells were saturated 
by incubation with 2% BSA in PBST (1 h, 37°C). After washing with PBST, 50 µL triplicates 
of diluted mouse sera (1:50, 1:150, 1:300 and 1:600), or human sera (1:50, 1:200, 1:800 and 
1:3200) in PBS containing 1% BSA were added to the wells and incubated overnight at 4°C. 
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Bound antibodies were detected colorimetrically as described above. Cutoff curves with a 
confidence level of 95% were determined based on control group data (244). The endpoint 
titer was as the interception of the regression line of the cutoff values and the regression line 
of the sample values, if the titer was lower than the reciprocal of the highest serum dilution 
tested. Higher titers were calculated as the interception between the regression line of the 
sample and the constant line determined by extrapolation of the cut of curve.  
To determined the specificity of PARF-tandem antibodies in rabbit serum 96-well plates were 
coated over night at 4°C with 4 µg/mL of recombinant StG11 1-A or StG120.1s. Bound IgG 
was detected colorimetrically using horseradish peroxidase-coupled secondary antibody (goat 
anti-rabbit IgG, Jackson Laboratories) and ABTS. Cutoff curves were based on rabbit pre-
immune serum. 
2.18 Binding of Spa proteins to collagen IV 
ELISA assay was performed to determine the binding between recombinant Spa proteins and 
collagen IV. A 96-well plate was coated overnight at 4°C with 5 µg/mL of collagen IV in 0.1 
M NaHCO3 (pH 9.0) and incubated for 1 h at 37°C with recombinant Spa18 or Spa36 (1 to 5 
dilution series). After washing with PBST, the wells were saturated by incubation with 2% 
BSA in PBST (1 h at 37°C). After a further washing step with PBST, 50 µL triplicates of 
mouse serum (diluted 1:100) from animals injected with recombinant Spa18 was added to the 
wells and incubated overnight at 4°C. Bound IgG was detected colorimetrically using 
horseradish peroxidase-coupled secondary antibody as described above. 
2.19 Histology 
Heart tissues of the immunized mice were fixed in 3.7% formalin for 24 hours. Samples were 
further processed and examined at the Department of Pathology of the University of 
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Veterinary Medicine, Hannover, Germany. The samples were embedded in paraffin wax, 
sectioned and stained with hematoxylin and eosin for light microscopy.  
2.20 Production of rabbit antiserum  
Antiserum was produced by Davids Biotechnologie (Regensburg, Germany) by immunization 
of a rabbit with 100µg of PARF-tandem in a defined adjuvant 5 times, over a period of 60 
days. Antiserum was collected two weeks after the final injection. 
2.21 Bactericidal activity of PARF-tandem antiserum 
The bactericidal activity of the rabbit antisera against S. pyogenes was measured as described 
previously with some modifications (245-246). Human neutrophils were isolated from blood 
of healthy volunteers using Polymorphprep (Axis-Shield, Norway) following the 
manufacturer’s instructions. Isolated neutrophils were resuspended in RPMI medium (Sigma-
Aldrich). Neutrophils (5 x 10
5
 in 90 µL) were seeded per well of a 96 well plate. S. pyogenes 
strains stG11 (G45) and ΔstG11 (G89) were grown in THY medium to an optical density of 
0.4 at 600 nm wave length. 50 µL of the bacterial culture was pre-incubated with 50 µL of 
anti-PARF tandem serum or pre-immune serum at 37°C for 20 min. Then 10 µL of the 
bacteria-serum mix was added to the neutrophils resulting in a multiplicity of infection (MOI) 
of 1 to 2 and incubated for 1 h at 37°C. Then, the bacteria were recovered from the 96-well 
plate and the number of colony forming unit (CFU) was determined by plating dilutions on 
blood agar plates. The bactericidal assay was repeated on three separate occasions. 
To assess extracellular killing, neutrophils were pre-incubated with 1 μM cytochalasin D 
(Sigma-Aldrich) for 30 min at 37°C before adding streptococci. 
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CHAPTER 3 
Results 
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3.1 Autoimmune responses in ARF patients 
Sera of ARF patients were examined for presence of and possible interdependences between 
autoimmune responses in ARF. Samples of six healthy donors from the same geographic 
region were used to determine the cut-off curve for calculation of the titer. Eight out of 13 
tested patients had a significantly elevated titer against at least one of the tested autoantigens: 
collagen I, collagen IV, myosin and laminin (Fig. 13). In four out of these eight patients, 
elevated autoimmune responses against collagens were concomitant with responses against 
myosin. Three out of these four patients had elevated titers against laminin, too. No link 
between the autoimmune responses was observed in the 
patients.
 
Figure 13: Antibody responses against collagen I, IV, laminin and myosin in ARF patients. A total of 13 
sera of ARF patients were tested. Titers are shown for the eight out of 13 ARF patient sera that reacted at least 
against one out of the four tested autoantigens. The patient number is given on the x-axis.  
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3.2 Binding of collagen I and IV to S. pyogenes and SDSE 
Streptococci bind collagen I and IV in a PARF-dependent (59-101-102-247) or in a PARF-
independent manner (113-196). In a comparative experiment with streptococci of emm-types 
emm1, emm3.1, emm3.23, emm18, emm31, emm55, stG2078 and stG11, only isolates with a 
PARF-positive M protein and the highly encapsulated emm18 isolate bound radiolabelled 
collagen I and IV with high capacity (Fig. 14). Types emm1 and stG2078 that lack PARF and 
emm55 that bears an ineffective collagen binding motif (59) had the lowest binding capacity 
for both types of collagen. The PARF-negative isolate of type stG2078 bound significantly 
more collagen IV than other PARF-negative or M protein deficient isolates. Isolates of types 
emm1 and emm55 bound collagen at the same level as the M protein deficient mutants M1 
(emm1) and G89 (stG11) indicating that M1 and M55 protein did not contribute 
measurably to collagen binding. In absence of PARF or M protein, SDSE (G236, G89) bound 
more collagen I than S. pyogenes (A576, A799, A800, M1, M1). 
 
 
 
 
 
 
 68 
 
A 
 
B 
 
Figure 14: Binding of collagen to S. pyogenes and SDSE. The binding capacity for 
125
I-labelled collagen I (A) 
and IV (B) was expressed as the bound percentage of added radiolabelled collagen (black bars) for isolates 
indicated on the x-axis. Error bars indicate the standard deciation of the triplicate measurements. All isolates 
belonged to the species S. pyogenes except of the SDSE isolates G45, G89 and G236. Isolates of types emm3.1, 
emm3.23, emm31, emm55 and stG11 carried M proteins with PARF motif. 
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3.3 Binding of collagen I and IV to M protein and Spa 
Binding of collagen type I and IV was investigated in ligand blots with recombinant M 
proteins, including stG11AA, a variant of stG11 (also known as FOG) with inactivated PARF 
motif (ARAAQKLN) (101). Collagen I bound to 1 µg spotted M3.0 protein and, in a 
concentration dependent manner, to stG11 (Fig. 15). 
          
Figure 15: Binding of collagen I and IV to M proteins in a ligand overlay assay. Binding of radiolabelled 
collagen I (left) and collagen IV (right) to immobilized M proteins that are indicated on the left, was detected 
radiographically. Amounts of immobilized M protein are indicated below. Only a week signal for binding of 
collagen I to M3.0 at 1 µg could be detected.  
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Similarly, collagen IV interacted with stG11, M3.0 and M3.23 in a concentration dependent 
way, but with different affinity. As it was relevant for the interpretation of the immunization 
experiments that are presented below, the apparent dissociation constants for the interaction 
between collagen IV and stG11, M3.0 and M3.23 were determined by biolayer interferometry 
(BLI) as 15 nM, 52 nM and 160 nM, respectively (Fig 17). Notably, M3.23 differs from M3.0 
in three amino acids, in position 31, 98 and 121 while PARF motif was located in positions 53 
to 60 (Fig. 16).  
 
Figure 16: Alignment of M proteins M3.0 and M3.23. Partial protein sequences of two M3 protein sub-types 
M3.0 and M3.2 are depicted. The PARF motif is marked by a box. Characteristic amino acids of the PARF-
consensus are indicated in bold. M protein designations are given on the left. Numbers that flank the sequences 
indicate their positions within the full length sequence of the mature protein without signal peptide. Substituted 
amino acids are highlighted in grey. Identical amino acids (*), conserved substitutions (:), and semi-conserved 
substitutions (.) are indicated below. 
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The decreased affinity of M3.23 for collagen IV, as compared to M3.0, indicates structural 
influences of other parts of the M protein other than PARF that impair collagen binding, as 
suggested previously (247). Despite lower affinity of M3.23, the corresponding emm3.23 
isolate A856 had a high binding capacity for collagen IV. Potential reasons are a high avidity 
for collagen IV on the bacterial surface due to a high number of M3.23 molecules or 
additional or alternative collagen binding factors on A856. As in the ligand blot, no 
interaction was detected in BLI between collagen IV and M proteins stG11AA (Fig. 17 B), 
M1, M55 or stG2078. In accord with our previous observations and the binding experiments 
with bacteria that are described above, binding of M protein to collagen I and IV was limited 
to PARF-positive M proteins, but not all PARF-positive M proteins bound collagen with high 
affinity (59-101-102).  
 
A 
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Figure 17: Binding of M proteins to immobilized collagen IV in BLI measurements with SA biosensors. 
Sensograms show the association (0-500 s) and dissociation (500-700 s) of the M proteins stG11 (A), stG11 AA 
(B), M3.0 (C), M3.23 (D) in a concentration of 40 µg/mL (red line) 10 µg/mL (black line) and 5 µg/mL (green 
line).  
Binding of collagen I and IV to 4µg spotted Spa18 and Spa 36 was observed in a ligand blot 
experiment (Fig. 18). Collagen IV interacted with Spa18 and Spa36 in a concentration 
dependent way, but with different affinity.  
 
Figure 18: Binding of collagen I and IV to Spa proteins in a ligand overlay assay. Binding of radiolabelled 
collagen I (left) and collagen IV (right) to immobilized Spa proteins was detected radiographically. Amount of 
immobilized protein is indicated below. Only a week signal for binding of collagen I to Spa36 at 4 µg could be 
detected.  
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Binding of Spa proteins to collagen IV was confirmend by an ELISA experiment (Fig. 19).  
 
Figure 19: Binding of Spa proteins to 96-well plate coated with collagen IV. Concentration of recombinant 
Spa18 (red line) and Spa36 (green line) is given on the x-axis (µM), value of optical density is given on the y-
axis.  
3.4 Induction of autoantibody production by M proteins and 
Spa18 in vivo 
Recombinant M proteins that differed in affinity for collagen IV were examined for their 
ability to induce the production of antibodies against collagen IV, myosin and laminin in 
mice. Reactivity against these autoantigens has been implicated in ARF pathogenesis (101-
113-174). In addition, antibody titer against collagen I was determined and it was sought for 
causative connections between the investigated autoimmune responses (Fig. 20). Heart of 
mice that mounted autoimmune responses against collagen IV and other autoantigens were 
devoid of histopathological abnormalities in heart musculature and valves. 
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Figure 20: Antibody responses against collagen I, IV, laminin and myosin induced in mice by M proteins. 
Mean titers are shown for each group of mice, which were immunized with the M protein that is given on the x-
axis. The ability of the respective M protein to bind collagen I or IV is indicated below. +++ high affinity, ++ 
intermediate affinity, + low affinity, - no binding detected.  
Elevated response against myosin arose in the groups of mice that were immunized with 
stG11 AA (titer = 143) and stG2078 (titer = 643). Anti-myosin response that occurred in these 
mice did not coincide with an anti-laminin response, which was observed in the groups of 
mice that received stG11 or M3.0. The results indicate no or low crossreactivity between 
laminin and myosin autoantibodies in the utilized in vivo model for induction of 
autoimmunity by M protein. 
All the M proteins induced collagen I autoimmunity in mice, except of M3.23. This induction 
of autoimmunity did not depend on the presence of a functional PARF motif because it also 
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occurred in the groups of mice that were injected with stG11AA, M1 or stG2078, which lack 
a PARF motif.  
In contrast, the experiments unambiguously demonstrated that collagen IV autoimmunity, 
caused by M protein, depends on a fuctional PARF motif. Antibody titers against collagen IV 
increased significantly only upon injection of stG11 (titer = 629) or M3.0 (titer = 456), which 
both bind collagen IV with high affinity via a PARF motif. Injection of M55 or M3.23, which 
have a lower affinity for collagen IV as compared to stG11 or M3.0 (Fig. 20), did not evoke 
collagen IV autoimmunity, indicating that PARF-positive M proteins require a certain affinity 
for collagen IV to trigger this autoimmune response (Fig. 20). 
Interdependences between anti-collagen and anti-myosin responses could be excluded (Fig. 
20). None of mice that developed autoimmunity against myosin showed a significant response 
against collagen IV, excluding that collagen IV autoimmunity is a side-effect of the 
previously described molecular mimicry of myosin (174).  
Notably, elevated titers against laminin occurred exclusively in the groups of mice that were 
injected with M proteins that triggered collagen IV autoimmunity, M3.0 (titer = 1078) and 
stG11 (titer = 587). This suggests that collagen IV autoimmunity preceded laminin-specific 
responses in this in vivo model rather than the reverse. However, an experiment with Spa18 
does not suggest a causative connection between these two responses (Fig. 21). 
Taken together, the experiments prove that the collagen binding PARF motif is a specific 
trigger of collagen IV autoimmunity in vivo.  
Spa is a M-like protein that is predicted to form a coiled coil structure and is located on the 
surface of S. pyogenes of emm-types 18 (Spa18) and 36 (Spa36). Spa18 and Spa36 did not 
harbour a PARF motif but bound to collagen IV (3.3, Fig. 17 and 18). As S. pyogenes of emm-
type 18 caused several ARF outbreaks in the USA (142) Spa18 was investigated in our 
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established in vivo model as a possible trigger of collagen IV autoimmunity and of the other 
ARF-related autoimmuneresponses (3.1, Fig. 13). In particular, Spa18 was examined for its 
ability to induce the production of antibodies against collagen I, collagen IV, myosin and 
laminin in mice (Fig. 21). 
Notably, Spa18 trigger autoimmunity against collagen I (titer = 303), collagen IV (titer = 641) 
and myosin (titer = 624), but not anti-laminin response. 
 
 
Figure 21: Antibody responses against collagen I, IV, laminin and myosin induced in mice by Spa18 
protein. Mean titers for the group of immunized mice are given on the y-axis.  
The lack of correlation between the investigated autoimmune responses in the experiments 
with M proteins and Spa is in accordance with the responses that were observed in ARF 
patients (3.1). A causative connection beween anti-collagen and anti-coiled-coil responses is 
not suggested by the presented data. 
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3.5 Binding of collagen IV to PARF tandem protein 
PARF tandem consist of all the PARF motif known to date. This makes the recombinant 
PARF tandem a valuable tool to develop a vaccine that protect against all the S. pyogenes and 
SDSE that harbour PARF-containing M protein. Several experiments show that M protein that 
harbour PARF motif and synthetic PARF peptides bind to collagen IV with different affinity. 
However, the binding of PARF tandem protein to collagen types needed to be examined. 
Binding of PARF tandem to collagen type IV was investigated in ligand blots (Fig. 22). 
Collagen IV bound to the spotted PARF tandem protein in a concentration dependent manner, 
however, the PARF tandem construct did not bind to collagen I in ligand blot assay (Fig. 22). 
 
 
Figure 22: Binding of collagen I and IV to PARF-tandem protein in a ligand overlay assay. Binding of 
radiolabelled collagen I (left) and collagen IV (right) to immobilized PARF-tandem protein was detected 
radiographically. The amount of immobilized protein is indicated below. 
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3.6 Immunity against PARF tandem and its reactivity against 
PARF containing M proteins 
PARF tandem antigen is a potent inducer of specific antibodies in rabbit (Fig. 23). Moreover, 
the serum reacted against the N terminal part of StG11 (named StG11 1-A) and StG120.1 
(named StgG120.1s), which both carry a PARF motif. The experiment was carried out with 
N-terminal fragments, which, in contrast to the full length M proteins, do not bind IgG by the 
Fc-region (248). The result indicates that PARF tandem evokes immune responses against 
PARF containing M proteins, presumably due to antibodies that react against PARF. The 
exact specificity of the antibodies requires further investigation. 
 
 
Figure 23: Reactivity of PARF tandem antiserum that was raised in rabbit. The titers of rabbit antibodies 
against PARF tandem and the N-terminal fragment of M protein stG11 and stG120.1s are given on the y-axis. 
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3.7 Opsonizing activity of antibodies against PARF tandem  
To determine the opsonizing activity of the antibodies that were produced in response to 
immunization with the PARF tandem antigen, an in vitro test was performed using the strain 
stG11, that harbors a M protein with a PARF motif (StG11) and its natural mutant, the strain 
ΔstG11 that does not express M protein on its surface. The bactericidal assay determined the 
percentage of streptococci that survived exposure to human neutrophils after pre-incubation 
with either pre- or immune rabbit serum. Immune rabbit serum was opsonizing and 
bactericidal just for strain stG11 (37% of survival), indicating that the bactericidal activity of 
the serum depended largely on M protein specific opsonization (Fig. 24). 
 
Figure 24: Effect of PARF tandem antiserum on the bactericidal effect of human neutrophils in vitro). 
Survival rate of SDSE stG11 that expressed a PARF positive M protein and its isogenic mutant ΔstG11 that 
lacked M protein on its surface is indicated on the y-axis. As indicated on the x-axis, the bacteria were pre-
incubated either in serum of a rabbit that was immunized with PARF (immune) or with the pre-immune serum 
of the same animal. The survival of stG11 preincdubated in rabbit sera is significantly reduced (p value < 0.0001, 
***) when compared to stG11 non incubated in rabbit sera. Experiment performed by Dr. Uchiyama, HZI 
Braunschweig. 
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3.8 Induction of autoantibody production by peptide 17 and 
PARF-tandem in vivo 
The synthetic PARF peptide (peptide 17) and its scrambled control (peptide 18) were 
examined for their ability to induce the production of autoantibodies against collagen IV in 
mice. Injection of peptides 17 and 18 did not evoke collagen IV autoimmunity, suggesting 
that the small PARF containing peptide 17 may not be sufficient to induce autoimmuninity in 
our animal model. Secondary structure prevision indicated that peptide 17 do not form coil-
coiled, a property of full-lenght M protein. This characteristic may be crucial to explain the 
the lack of autoimmunity against the peptide 17. In fact, although the affinity to collagen IV 
for peptite 17 is moderate, the lack of seconday structures may reduce its avidity for collagen 
and decrease the adherence properties that the PARF motif confers to M proteins. 
Notably, antibody titers against collagen IV (titer = 307) and myosin (titer = 804) increased 
significantly only upon injection of PARF tandem (Fig. 25). In contrast, PARF-tandem did 
not trigger autoimmunity against collagen I or laminin in the mice. 
Elevated response against collagen IV or myosin was concomitant in 7 out of 10 mice injected 
with PARF tandem. However, a causative connection between anti-collagen IV and anti-
myosin response was excluded by the experiment with full-lenght M proteins. 
PARF-tandem lacked heptad repeat structures. Therefore, induction of myosin autoimmunity 
by PARF tandem did not depend on the presence of a coiled-coil structure. This suggests that 
molecular mimicry was either independent of the coiled-coil structure or the autoimmune 
response against myosin was caused by an alternative mechanism. Binding of myosin to 
PARF-tandem remains to be tested. 
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Figure 25: Antibody responses against collagen I, IV, laminin or myosin induced in mice by PARF tandem 
protein. Mean titers for the group of immunized mice are given on the y-axis. Specificity of the antibodies is 
given on the x-axis.  
The injection of PARF tandem led to antibody responses against collagen IV and myosin in 
the animal model. This is further evidence for the role of PARF as the trigger of 
autoimmunity. In addition, the result indicates that PARF containing antigens when used for 
immunization are associated with a risk of side effects.  
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CHAPTER 4 
General discussion 
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4.1 General discussion 
Destructive autoimmune responses in ARF are limited to the extracellular matrix (ECM), as 
indicated by histopathological examinations on patient samples (166). This includes 
rheumatic carditis, which is a frequent manifestation of ARF and the suspected cause of RHD. 
Histopathologically, rheumatic carditis presents as an interstitial carditis, rarely showing signs 
of myocarditis. Moreover, markers for myocardial damage, such as troponins and creatine 
kinase, are not significantly elevated in these patients (166-249). Since cardiac myosin is 
localized inside the myocyte, these observations suggest that this host protein is not a primary 
target for the poly-reactive autoimmune responses in ARF (65-166-174). Instead, they could 
react with coiled-coil proteins in the ECM, basement membranes or on the cell surface. One 
potential target is laminin that forms a triple-helical coiled-coil and is recognized by 
monoclonal antibodies from patients with rheumatic carditis (250). Like collagen IV, laminin 
is a major component of basement membranes (251), including the basement membranes that 
support the endothelium of heart valves. Therefore, autoimmunity against these proteins may 
be directly involved in the degeneration of the heart valves in RHD. 
Notably, reactivity against all the tested autoantigens collagen I and IV, laminin and myosin 
was observed in ARF patients (Fig. 13). However, no correlations between these responses 
were observed. A low degree of cross-reactivity between anti-myosin and anti-laminin 
responses was noted, which indicates that the triggering factors were not limited to previously 
identified molecular mimicry epitopes that lead to the production of poly-reactive antibodies. 
An association of anti-laminin responses with M proteins that triggered collagen IV 
autoimmunity via a PARF motif (Fig. 20) was not supported by the experiment with PARF 
tandem (Fig. 25). Moreover, PARF-independent induction of collagen IV autoimmunity by 
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Spa18 was not concomitant with anti-laminin reactivity (Fig. 21), which also speaks against a 
causative connection between these responses.  
After injection of M protein, mice that mounted an autoimmune response against collagen IV 
and other autoantigens did not develop relevant pathologic changes in cardiac tissue during 
the short period of the experiment. Thus, the utilized in vivo model was restricted to processes 
that are likely to precede manifestation of ARF. Consequently, it is unlikely that the observed 
immune responses are not secondarily caused by tissue damage. 
The ability of M proteins to trigger collagen IV autoimmunity is confirmed, associated with 
the N-terminal part of the protein (101) and unambiguously linked to the PARF motif (Fig. 
20). The underlying molecular and cellular mechanisms of PARF-dependent autoimmunity 
are not yet explored, but appear to involve collagen binding. Moreover, the causes for the 
autoimmune responses against collagen I and in part of laminin and myosin remain elusive. 
Autoimmunity against collagen I was not associated with the function of PARF (Fig. 20 and 
25). Induction of immunresponses against laminin was limited to M proteins that bound 
collagen with high affinity (Fig. 20), thus may involve an alternative mechanism to molecular 
mimicry. Similarly, myosin autoimmunity was triggered by PARF tandem that lacks the 
heptad repeads for coiled coil structures, which could cause molecular mimicry (Fig. 25). 
Further research on the causes of these responses is needed. 
PARF is an epidemiologically relevant collagen binding motif that occurs in about 7% of the 
S. pyogenes isolates from human infections. Moreover, the discovery of Spa as a novel 
collagen binding protein that triggers autoimmunity against collagen IV, despite lacking a 
PARF motif, broadens the spectrum of potential rheumatogenic factors in S. pyogenes. Spa18 
is the first trigger of autoimmunity that was identified in emm-type18, which caused several 
outbreaks of ARF in the USA (72-142-182). Some emm1 and emm18 isolates are 
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encapsulated by hyaluronic acid and this capsule has been suspected as the collagen binding 
factor of emm18 isolates. (113) However, an ability of hyaluronic acid to trigger collagen 
autoimmunity has not been shown. 
Only emm18 and PARF-positive S. pyogenes or SDSE bound collagen I or IV with high 
capacity in this or previous studies (102-113-250). Previously reported binding of collagen I 
or IV to emm1 (196) was not detectable in comparative binding experiments neither with 
whole bacteria nor with recombinant M protein (Fig. 14 and 15). Moreover, a previous 
experiment excluded an interaction between the PARF-negative protein M18 and collagen IV 
(113). Thus, hyaluronic acid (113) or other factors such as Slr (196), Cpa (195) or Spa18 
(141) may be employed for collagen binding by PARF-negative S. pyogenes. So far, an 
ability other factors than M proteins to trigger autoimmunity is only shown for Spa18. 
The utilized in vivo model identified early antibody responses to M protein and showed that 
PARF and molecular mimicry are independent triggers of autoimmunity. In ARF, additional 
streptococcal factors, individual conditions in the host and progression of the pathogenesis 
may have contributed to the diversity of autoimmune responses that was observed between 
different patients (Fig. 13). In four out of the total of 13 examined patient sera, no reactivity 
against any of the examined autoantigens was detected. The reactivity may have ceased 
during the course of diseases or other than the examined autoantigens may have been 
involved in these cases. By causing inflammation, tissue damage and epitope spreading, initial 
autoimmunity against one or a few proteins of the extracellular matrix may initiate a cascade 
of autoimmune responses that lead to the various symptoms of ARF. Only seemingly, this is 
contradictive to the specificity of the degenerative processes for the heart valve in subsequent 
RHD, which may ground on a limited ability of this tissue to heal and to resolve the 
destructive autoimmune responses, rather than on the specificity of the autoimmune responses 
(166). In this concept of ARF pathogenesis, single autoimmune responses caused by PARF or 
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molecular mimicry have a triggering function. Occurring in 8 out of 13 patients they may be 
valuable diagnostic and prognostic markers for ARF and RHD. As the responses in the in vivo 
model, the responses in patients indicate that PARF-induced autoimmunity and molecular 
mimicry are two independent triggering pathomechanisms of ARF, but they may act 
synergistically in some of the patients as they have been co-detected in four out of the 13 
patients. 
For the first time we proved that the PARF motif is an antigenic part of M protein and 
injection of PARF tandem in animals produced emm-type specific antibodies (Fig. 23). These 
antibodies may be a useful tool for detection of rheumatogenic streptococci, An antibody-
based test would improve diagnosis by identifying patients with an increased risk to fall ill 
with ARF or RHD.  
PARF tandem evoked the production of opsonizing antibodies in rabbit (Fig. 24) and could be 
an interesting vaccine candidate. Including PARF in vaccines may protect against the 
infection caused by PARF-positive S. pyogenes (emm3, emm31 and emm55) but also SDSE 
(Supplement D) broadning the coverage of a streptococcal vaccine by targeting isolates with 
the potential to cause collagen IV autoimmunity. However, the in vivo experiments indicated 
the possibility of immune side-effects (Fig. 25), thus, the 20-valent PARF tandem in its 
present form may be not safe for use in humans. A PARF-based or PARF-containing vaccine 
would require a careful redesign. 
In summary, the presented data provide evidence that collagen IV autoimmunity is 
specifically induced by PARF. Thus, it is independent of other host responses to M protein. 
However, it requires further investigations to elucidate the role of collagen IV binding in this 
barely understood immune response. Other streptococcal factors, as shown for Spa18, trigger 
autoimmunity in a similar way. A better understanding of the underlying processes will help 
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to conceive preventive measures against ARF. Moreover, it may also increase our 
understanding of other rheumatic diseases that may originate from noxious host-microbe-
interactions. 
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SUPPLEMENTS  
Supplement A: FASTA files of the recombinant proteins used in this work. Molecular 
weight is expressed in kDa and was calculated using ProtParam. http://web.expasy.org/cgi-
bin/protparam/protparam 
>StG11 (Fog) (65.247 kDa) 
HHHHHHGENLYFQGSAENTYDRWKAQTEEARTDKLIAGFANLDADVTNLGKMMDELQKLKDFSKQNNSIGEYAR
YLQKLNDQFQEYYEQVVGDDSRRVLAKELAKNTELNEKLSELSKTSQALAKELQEQKENYDLVKTVHADTVKKHQ
KLVDEITKKLGEEETERHSLQEELNKAQQELAQKQQELKDKQADYDLVVETHAYTVKEHQKLVDEITKKLGEEETE
RHSLQEELNKAQQELAQKQQELEAEKLAKEGIVDSLTAYVTEKEAEVKKLTDSLAAKDAEIQEKEAEKDRQQHMY
EAFMSQYKEKVEKQEQELAKLKQLETINNNLLGNAKDMIAKLSAKNEQLASDKAKLEEQNKISDASRKGLRRDLNA
SREAKKQLEAEHQKLEEQNKISEASRKGLRRDLDASREAKKQVEKDLANLTAELDKVKEDKQISDASRKGLRRDL
DASREAKKQVEKALEEANSKLAALEKLNKELEESKKLTEKEKAELQAKLEAEAKALKEKLAKQAEELAKLRAGKAS
DSQTPEATPGNKVVPGKGQASQAGTKPNQNKEPMKETKRQLPSTG 
>StG11 AA (Fog AA) (65.247 kDa) 
HHHHHHGENLYFQGSAENTYDRWKAQTEEARTDKLIAGFANLDADVTNLGKMMDELQKLKDFSKQNNSIGEYAR
AAQKLNDQFQEYYEQVVGDDSRRVLAKELAKNTELNEKLSELSKTSQALAKELQEQKENYDLVKTVHADTVKKH
QKLVDEITKKLGEEETERHSLQEELNKAQQELAQKQQELKDKQADYDLVVETHAYTVKEHQKLVDEITKKLGEEET
ERHSLQEELNKAQQELAQKQQELEAEKLAKEGIVDSLTAYVTEKEAEVKKLTDSLAAKDAEIQEKEAEKDRQQHM
YEAFMSQYKEKVEKQEQELAKLKQLETINNNLLGNAKDMIAKLSAKNEQLASDKAKLEEQNKISDASRKGLRRDLN
ASREAKKQLEAEHQKLEEQNKISEASRKGLRRDLDASREAKKQVEKDLANLTAELDKVKEDKQISDASRKGLRRD
LDASREAKKQVEKALEEANSKLAALEKLNKELEESKKLTEKEKAELQAKLEAEAKALKEKLAKQAEELAKLRAGKA
SDSQTPEATPGNKVVPGKGQASQAGTKPNQNKEPMKETKRQLPSTG 
>StG11 1A (Fog1-A) (15.533 kDa) 
AENTYDRWKAQTEEARTDKLIAGFANLDADVTNLGKMMDELQKLKDFSKQNNSIGEYARYLQKLNDQFQEYYEQ
VVGDDSRRVLAKELAKNTELNEKLSELSKTSQALAKELQEQKENYDLVKTVHADTVKKHQ 
>M1 (AP1) (48.608 kDa) 
HHHHHHGENLYFQGSNGDGNPREVIEDLAANNPAIQNIRLRHENKDLKARLENAMEVAGRDFKRAEELEKAKQA
LEDQRKDLETKLKELQQDYDLAKESTSWDRQRLEKELEEKKEALELAIDQASRDYHRATALEKELEEKKKALELAI
DQASQDYNRANVLEKELETITREQEINRNLLGNAKLELDQLSSEKEQLTIEKAKLEEEKQISDASRQSLRRDLDASR
EAKKQVEKDLANLTAELDKVKEDKQISDASRQGLRRDLDASREAKKQVEKDLANLTAELDKVKEEKQISDASRQG
LRRDLDASREAKKQVEKALEEANSKLAALEKLNKELEESKKLTEKEKAELQAKLEAEAKALKEQLAKQAEELAKLR
AGKASDSQTPDTKPGNKAVPGKGQAPQAGTKPNQNKAPMKETKRQLPSTG 
>M55 (56.463 kDa) 
HHHHHHGENLYFQGSQTEPSQTNNRLYQERQRLQDLKSKFQDLKNRSEGYIQQYYDEEKNSGSNSNWYATYLK
ELNDEFEQAYNELSGDGVKKLAASLMEERVALRDEIDQIKKISEELKNKLRAKEEELKNKKEERELEHAAYAADAK
KHEEYVKSMSLVLMDKEEERHKLEQSLDTAKAELVKKEQELQLVKGNLDQKEKELENEELAKESAISDLTEQITAK
KAEVEKLTQDLAAKSAEIQEKEAEKDRQQHMYEAFMSQYKEKVEKQEQELAKLKQLETINNNLLGNAKDMIAKLS
AENEQLASDKAKLEEQNKISEASRKGLRRDLDASREAKKQVEKDLANLTAELDKVKEDKQISDASRKGLRRDLDA
SREAKKQVEKSLEEANSKLAALEKLNKELEESKKLTEKEKAELQAKLEAEAKALKEQLAKQAEELAKLRAGKASDS
QTPDAKPGNKVVPGTGQAPQAGTKPNQNKAPMKETKRQLPSTG 
>StG2078 (63.128 kDa) 
HHHHHHGENLYFQGSVENTAQYDRQKAETEKNRIYGLERNLLDLKAQVDHLENLMDNLQTQKAFVNNLSWSDN
NIGEYAKLLEELNDQFEEYYEKVVGDDSRRVFAKVIEENKGLNEKLSGLLEKSNDLAKKLKEKEEELKNKEAERDL
EHAAYARDRKEHEEYVRRVGLLLEDRAKEKQELQSSVEQAKKKIDSLNQELAQKEEELAKEKLAKQGIIDSTSDYV
TEKESKIAKLEEEIQTNKAELESLNSQLESLNSNLDKKTSEIDNLKQELTRKENMYESFLNQAKENLASKEQELXKL
KQLETINNNLLGNAKDMIAKLSAKSEQLASDRAKLEEQNKISDASRQSLRRDLNASREAKKQLEAEHQKLEEQNKI
SEASRQGLRRDLNASREAKKQVEKDLANLTAELDKVKEEKQISDASRQGLRRDLEASREAKKQVEKALEEANSKL
AALEKLNKELEESKKLTEKEKAELQAKLEAEAKALREKLAKQAEELAKLRAGKASDSQTPDATPGNKVVPGKGQA
PQAGTKPNQNKAPMKETKRQLPSTG 
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>M3.23 (59434 kDa) 
HHHHHHGENLYFQGSDARSVNGEFPRHVKLKNEIENLLDQVTQLYNKHNSNYQQYNAQAGRLDLRQKAEYLKG
LNDWAERLLQELNGEDVKKVLGKVAFEKDDLEKEVKELKKKIDKKEKEYQDLDKDFDLAKQGHVLSDKRHQQELE
EKEKKVTEATAKVGQISEELETVKQKVESTMQDLTEKQNRVSQLEQELATTKQNAKEDFELAALANAADKQKLEA
KIADLETKLKEAKEDFELAALGHQHAHNEYQAKLAEKDDQIKQLEEQKQILDASRKGTARDLEAVRQAKKATEAEL
NNLKAELAKVTEQKQILDASRKGTARDLEAVRQAKAQVEAALKQLEEQNRISEASRKGLRRDLDASREAKKQVEK
DLANLTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSKLAALEKLNKELEESKKLTEKEKAELQ
AKLEAEAKALKEQLAKQAEELAKLRAGKASDSQIPDTKPGNKAVPGKGQAPQAGTKPNQNKAPMKETKRQLPST
G 
>M3.0 (59.448 kDa) 
HHHHHHGENLYFQGSDARSVNGEFPRHVKLKNEIENLLDQVTQLYTKHNSNYQQYNAQAGRLDLRQKAEYLKGL
NDWAERLLQELNGEDVKKVLGKVAFEKDDLEKEVKELKEKIDKKEKEYQDLDKDFDLAKQGYVLSDKRHQQELE
EKEKKVTEATAKVGQISEELETVKQKVESTMQDLTEKQNRVSQLEQELATTKQNAKEDFELAALANAADKQKLEA
KIADLETKLKEAKEDFELAALGHQHAHNEYQAKLAEKDDQIKQLEEQKQILDASRKGTARDLEAVRQAKKATEAEL
NNLKAELAKVTEQKQILDASRKGTARDLEAVRQAKAQVEAALKQLEEQNRISEASRKGLRRDLDASREAKKQVEK
DLANLTAELDKVKEEKQISDASRQGLRRDLDASREAKKQVEKALEEANSKLAALEKLNKELEESKKLTEKEKAELQ
AKLEAEAKALKEQLAKQAEELAKLRAGKASDSQIPDTKPGNKAVPGKGQAPQAGTKPNQNKAPMKETKRQLPST
G 
>StG120.1s (16.660 kDa) 
HHHHHHGENLYFQGSEENITQYDKWNWETQFGRTSDLTSKLQLLKDRVSGLEYIMNHLNSEIRPDKWQSHDLGV
LANYLKTLNDHFEENYEKVVGDDSRRVLAQEVEENRALKEKLSELTTKSEKLANELKAQQEIYQLAV 
>PARF tandem (38.037 kDa) 
HHHHHHGENLYFQGSLQQAEYLQRLNDHFEDVYTEYLKRLNDDAEAGRTEYLKSLNDWAEEQKAEYLRSLNDW
AEDTHTQYLKRLNDYFQEVYTQYLKRLNDQFQASVAVALTVLGAGLAKTYADYLKTLNDRFENTYTEYLKSLNDH
FQKDYANYLKELNDHFENWYATYLKELNDEFERQKAEYLKGLNDWAETQKAEYLKNLNDWAEGQMAEYLKALN
DHFEGVLANYLKTLNDHFEGEYARYLQKLNDQFQGVYARYLKKLNDQFQGVYARYLETLNDRFQGVYARYLKRL
NDHFQSDDEAYLKRLNEWAE 
>Spa18 (57704 kDa) 
HHHHHHGENLYFQGSDSVSGLEVADPSDSKKLIELGLAKYLNDKLPFKTKEDSEILSELRDVLKNANPETLKSLLN
GMDQGHISFSDRNNRYNRLSQYINSFRKDDDDYLHNGYSLGSLVIEAIKYRLDSESHLKEELLKQTAELEQRKNAE
VDLKSEKKRLEAQIEKVGYDIANKQQELEKARSDQKELSESIQKLTSRFKKESDAKQKELDEAKAANKSLSESATK
TLARSSKITNELKDKLAASEKDKNRAFQVSSELANKLHETETSRDKALAESKELADKLAVKTAEAEKLMENVGSLD
RLVESAKREMAQKLAEIDQLTADKAKADAELAAANDTIASLQTELEKVKTELAVSERLIESGKREIAELEKQKDASD
KALAESQANVAELEKQKAASDAKVAELEKEVEAAKAEVADLKAQLAKKEEELEAVKKEKEALEAKIEELKKAHAEE
LSKLKEMLEKKDHANADLQAEINRLKQELADRIKSLSQGGRASQTNPGSTTAKAGQLPSTG 
>Spa36 (55.381 kDa) 
HHHHHHGENLYFQGSEDRINSDINRRIVDKKDAENLRNAIIAKGARLKNDSEVISFLREALSNATVDTLATLLSGIDP
ARFGYSNSQLEFYSRQLGSLNSGVSDWQQGSVNLKTLLIEEFAKRIKSEQKLKEVLAEQAAELELRKSEESELKTQ
KERLESKLENAEYATAIKQKELDDAKEANKTLSESIAKTLSRSTKEKDKLKEELVKEKTKAAKIAKELMDKLTASEKD
KDRAIQITTELTNRLHETEASRDKAFAVSTELANKLAAKTAEAEKLMQNVGSLDRLVESAKREIAEKLAEIDQLTAD
KAKADAELATANDTIASLQTELEKAKTELAVSERLIESGKREMAELQKQKDASDKALAESQANVAELEKQKAASDA
KVAELEKEVEAAKAEVADLKAQLAKKEEELEAVKKEKEALEAKIEELKKAHAEELSKLKEMLEKKDHANADLQAEIN
RLKQELADRIKSLSQGGRASQANPGSTTAKAGQLPSTG 
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Supplement B: Modules of PARF tandem and optimized nucleotide sequences. 
Nucleotide sequence Amino acid sequence  
>LC1903optimized 
CTGCAGCAGGCAGAATATCTGCAGCGTCTGAACGATCATTTTGAA 
>stGrobn.0optimized 
GATGTGTATACCGAGTATCTGAAACGCCTGAATGATGATGCAGAA 
>stG211.0optimized 
GCAGGTCGTACGGAATATCTGAAATCACTGAACGATTGGGCAGAA 
>stG211.1optimized 
GAACAGAAAGCAGAGTATCTGCGTAGTCTGAATGACTGGGCTGAA 
>stC2sk.0optimized 
GATACCCATACCCAATACCTGAAACGGCTGAACGATTATTTCCAA 
>stG97.0optimized 
GAAGTTTATACGCAGTACCTGAAACGTCTGAATGACCAGTTTCAG 
>stG4545.0optimized 
GCAAGCGTTGCAGTTGCACTGACCGTTCTGGGTGCAGGTCTGGCA 
>stC6746.0optimized 
AAAACCTATGCAGATTATCTGAAAACTCTGAATGATCGCTTCGAG 
>stCQ343.0optimized 
AACACCTACACCGAATACCTGAAATCCCTGAATGATCACTTTCAG 
>stC46.0optimized 
AAAGATTACGCCAACTATCTGAAAGAGCTGAACGACCACTTTGAA 
>emm55.0optimized 
AATTGGTATGCAACCTACCTGAAAGAACTGAATGACGAATTTGAG 
>emm3.0optimized 
CGTCAGAAAGCCGAGTACCTGAAAGGACTGAACGACTGGGCTGAG 
>emm31.5optimized 
ACTCAGAAAGCTGAATATCTGAAAAACCTGAATGACTGGGCAGAG 
>stG10.0optimized 
GGTCAGATGGCAGAGTATCTGAAAGCCCTGAACGATCATTTCGAG 
>stG120.1optimized 
GGTGTTCTGGCAAATTACCTGAAAACCCTGAACGACCACTTCGAA 
>stG11.0optimized 
GGCGAATATGCACGTTATCTGCAGAAACTGAATGATCAGTTCCAG 
>stG351.0optimized 
GGTGTGTATGCCCGTTACCTGAAAAAACTGAACGATCAATTTCAG 
>stC5344.0optimized 
GGCGTTTATGCGCGTTATCTGGAAACGCTGAACGACCGTTTTCAG 
>stC-NSRT2.0optimized 
GGTGTATACGCACGCTATCTGAAACGTCTGAACGATCACTTTCAG 
>stG2574.0optimized 
AGTGATGATGAAGCATATCTGAAACGGCTGAATGAATGGGCAGAA 
>LC1903optimized 
LQQAEYLQRLNDHFE 
>stGrobn.0optimized 
DVYTEYLKRLNDDAE 
>stG211.0optimized 
AGRTEYLKSLNDWAE 
>stG211.1optimized 
EQKAEYLRSLNDWAE 
>stC2sk.0optimized 
DTHTQYLKRLNDYFQ 
>stG97.0optimized 
EVYTQYLKRLNDQFQ 
>stG4545.0optimized 
ASVAVALTVLGAGLA 
>stC6746.0optimized 
KTYADYLKTLNDRFE 
>stCQ343.0optimized 
NTYTEYLKSLNDHFQ 
>stC46.0optimized 
KDYANYLKELNDHFE 
>emm55.0optimized 
NWYATYLKELNDEFE 
>emm3.0optimized 
RQKAEYLKGLNDWAE 
>emm31.5optimized 
TQKAEYLKNLNDWAE 
>stG10.0optimized 
GQMAEYLKALNDHFE 
>stG120.1optimized 
GVLANYLKTLNDHFE 
>stG11.0optimized 
GEYARYLQKLNDQFQ 
>stG351.0optimized 
GVYARYLKKLNDQFQ 
>stC5344.0optimized 
GVYARYLETLNDRFQ 
>stC-NSRT2.0optimized 
GVYARYLKRLNDHFQ 
>stG2574.0optimized 
SDDEAYLKRLNEWAE 
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Supplement C: Coiled-coil formation predicted for protein StG11 (C1) and PARF 
tandem (C2) using Paircoil2 (252). P-score cutoff is 0,025 (dot line). Residues below this 
score are predicted to be in a coiled-coil. Minimum search window length:28. 
 
C1.  
 
 
C2.  
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Supplement C: Known S. pyogenes and SDSE emm-types that contain a PARF motif. 
 
 
 
S. pyogenes    S. dysgalactie subsp. equisimilis 
emm3 
 
emm31 LC1903    
 emm31 
 
stG10  stGrobn 
 emm55 
 
stG120  stG211 
 
  
stG11 stC2sk  
 
  
stG351  stG97 
 
  
stC5344 stG4545  
 
  
stC-NSRT2  stC6746  
 
  
stG2574 stCQ343  
 
  
LC1904 stC46 
  
  
